{"content":"<li class=\"n-box-item date-title\" data-end=\"1507780799\" data-start=\"1507694400\" data-txt=\"Monday, December 23, 2019\">Wednesday, October 11, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3300571\" data-ts=\"1507761484\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XL\" target=\"_blank\">XL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300571-xl-estimates-q3-catastrophe-losses-1_48b\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">XL estimates Q3 catastrophe losses at $1.48B</a></h4><ul>     <li>XL&nbsp;Group (NYSE:<a href='https://seekingalpha.com/symbol/XL' title='XL Group plc'>XL</a>) <font color='green'>+3.2%</font> after-hours as the insurance and reinsurance company said it expected to total <a href=\"https://seekingalpha.com/filing/3725893\" target=\"_blank\">~$1.48B in catastrophe losses in Q3</a>, mostly from hurricanes Harvey, Maria and Irma.</li>     <li>XL says its preliminary estimates are based on a combination of catastrophe modeling, exposure analysis and preliminary ground-up notifications and are consistent with private insured market loss estimates for the three hurricanes in the $75B-$90B range.</li>     <li>The company says it continues to have significant catastrophe reinsurance protections remaining for 2017 and 2018, including catastrophe bond protections, some of which extend through 2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300571\" data-linked=\"XL estimates Q3 catastrophe losses at $1.48B\" data-tweet=\"$XL - XL estimates Q3 catastrophe losses at $1.48B https://seekingalpha.com/news/3300571-xl-estimates-q3-catastrophe-losses-1_48b?source=tweet\" data-url=\"https://seekingalpha.com/news/3300571-xl-estimates-q3-catastrophe-losses-1_48b\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:38 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300570\" data-ts=\"1507761426\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WB\" target=\"_blank\">WB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300570-china-pressing-for-state-investments-in-key-tech-firms\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China pressing for state investments in key tech firms</a></h4><ul>   <li>China's government regulators are pushing some of the country's biggest tech firms to <a href=\"https://www.wsj.com/articles/beijing-pushes-for-a-direct-hand-in-chinas-big-tech-firms-1507758314\" target=\"_blank\">give the state a stake</a>, and a greater role in making corporate decisions, <i>The Wall Street Journal</i> reports.</li>    <li>Internet regulators are discussing the prospect of 1% stakes in a number of firms, including Tencent Holdings (<a href=\"http://seekingalpha.com/symbol/TCEHY\" target=\"_blank\">TCEHY</a> <font color='green'>+0.3%</font>), Weibo (NASDAQ:<a href='https://seekingalpha.com/symbol/WB' title='Weibo Corporation'>WB</a>) and Youku Tudou (now part of Alibaba (<a href=\"http://seekingalpha.com/symbol/BABA\" target=\"_blank\">BABA</a> <font color='green'>+0.9%</font>)).</li><li>The stakes come with the stipulation that investors appoint a government official to company boards and have say in their operations.</li>    <li>Even with a heavy hand in existing rulemaking, the regulators are concerned about the growing power of private business.</li>    <li>The government has begun its \"special management shares\" project with two media start-ups, taking stakes of less than 2% in mobile news site Yidian Zixun (<a href=\"http://seekingalpha.com/symbol/FENG\" target=\"_blank\">FENG</a> <font color='green'>+9.2%</font>) and Beijing Tiexue Tech, which operates a patriotic news site.</li>    <li>The report comes ahead of the Communist Party Congress, with the party pressing to take a greater role in Chinese society.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300570\" data-linked=\"China pressing for state investments in key tech firms\" data-tweet=\"$WB $WB $TCEHY - China pressing for state investments in key tech firms https://seekingalpha.com/news/3300570-china-pressing-for-state-investments-in-key-tech-firms?source=tweet\" data-url=\"https://seekingalpha.com/news/3300570-china-pressing-for-state-investments-in-key-tech-firms\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>89&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300569\" data-ts=\"1507759914\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BW\" target=\"_blank\">BW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300569-babcock-wilcoxplus-7-viex-capital-reports-active-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Babcock &amp; Wilcox +7% as VIEX Capital reports active stake</a></h4><ul>     <li>Babcock &amp; Wilcox Enterprises (NYSE:<a href='https://seekingalpha.com/symbol/BW' title='Babcock & Wilcox Enterprises, Inc.'>BW</a>) <font color='green'>+7.6%</font> after-hours as VIEX Capital Advisors <a href=\"https://www.sec.gov/Archives/edgar/data/1619125/000092189517002397/sc13d10114023_10112017.htm\" target=\"_blank\">discloses</a> a 6.4% stake (~2.83M shares) in the company, saying the shares are undervalued.</li>     <li>VIEX says BW's board needs to sell assets and make aggressive cost reductions, including corporate overhead, to enhance liquidity; without action,&nbsp;&nbsp; the firm says it may seek board changes at BW&rsquo;s 2018 annual shareholder meeting.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300569\" data-linked=\"Babcock &amp; Wilcox +7% as VIEX Capital reports active stake\" data-tweet=\"$BW - Babcock &amp; Wilcox +7% as VIEX Capital reports active stake https://seekingalpha.com/news/3300569-babcock-wilcoxplus-7-viex-capital-reports-active-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3300569-babcock-wilcoxplus-7-viex-capital-reports-active-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300565\" data-ts=\"1507758608\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LDR\" target=\"_blank\">LDR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300565-nmihplus-5_3-aclsplus-4_6-on-moves-smallcap-600\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NMIH +5.3%, ACLS +4.6% on moves into SmallCap 600</a></h4><ul>   <li>Insurance service provider NMI Holdings (<a href=\"http://seekingalpha.com/symbol/NMIH\" target=\"_blank\">NMIH</a> <font color='green'>+0.8%</font>) is <font color='green'>up 5.3%</font> after hours on word that it's <a href=\"https://www.spice-indices.com/idpfiles/spice-assets/resources/public/documents/597555_6scicllanax6.pdf?force_download=true\" target=\"_blank\">headed into the S&amp;P SmallCap 600</a>.</li>    <li>It will replace SciClone Pharmaceuticals (<a href=\"http://seekingalpha.com/symbol/SCLN\" target=\"_blank\">SCLN</a> <font color='green'>+0.9%</font>), set to be acquired by GL Capital Management, before the open on Monday.</li>    <li>Also joining the 600 is Axcelis Technologies (<a href=\"http://seekingalpha.com/symbol/ACLS\" target=\"_blank\">ACLS</a> <font color='green'>+1.4%</font>), <font color='green'>up 4.6%</font> in late trading. It will replace Landauer (<a href='https://seekingalpha.com/symbol/LDR' title='Landauer, Inc.'>LDR</a> <font color='green'>+0.4%</font>) before the open on Thursday, Oct. 19; Landauer is set to be acquired by Fortive in a deal closing soon.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300565\" data-linked=\"NMIH +5.3%, ACLS +4.6% on moves into SmallCap 600\" data-tweet=\"$LDR $LDR $NMIH - NMIH +5.3%, ACLS +4.6% on moves into SmallCap 600 https://seekingalpha.com/news/3300565-nmihplus-5_3-aclsplus-4_6-on-moves-smallcap-600?source=tweet\" data-url=\"https://seekingalpha.com/news/3300565-nmihplus-5_3-aclsplus-4_6-on-moves-smallcap-600\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:50 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300562\" data-ts=\"1507757803\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300562-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/ARDX' title='Ardelyx'>ARDX</a> <font color='green'>+36.1%</font>. <a href='https://seekingalpha.com/symbol/BW' title='Babcock & Wilcox Enterprises, Inc.'>BW</a> <font color='green'>+6.6%</font>. <a href='https://seekingalpha.com/symbol/XRF' title='China Rapid Finance'>XRF</a> <font color='green'>+3.4%</font>. <a href='https://seekingalpha.com/symbol/XL' title='XL Group plc'>XL</a> <font color='green'>+3.2%</font>. <a href='https://seekingalpha.com/symbol/RGNX' title='REGENXBIO'>RGNX</a> <font color='green'>+2.4%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/JILL' title='J. Jill Group, Inc.'>JILL</a> <font color='red'>-37.5%</font>. <a href='https://seekingalpha.com/symbol/PTGX' title='Protagonist Therapeutics'>PTGX</a> <font color='red'>-11.9%</font>. <a href='https://seekingalpha.com/symbol/NSTG' title='NanoString Technologies'>NSTG</a> <font color='red'>-9.8%</font>. <a href='https://seekingalpha.com/symbol/HAWK' title='Blackhawk Network Holdings, Inc.'>HAWK</a> <font color='red'>-7.2%</font>. <a href='https://seekingalpha.com/symbol/KNDI' title='Kandi Technologies Group, Inc.'>KNDI</a> <font color='red'>-5.5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300562\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$ARDX $BW $XRF - After Hours Gainers / Losers https://seekingalpha.com/news/3300562-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3300562-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300557\" data-ts=\"1507755868\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GSAT\" target=\"_blank\">GSAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300557-globalstar-closes-73_4m-share-public-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Globalstar closes 73.4M-share public offering</a></h4><ul>   <li>Globalstar (<a href=\"http://seekingalpha.com/symbol/GSAT\" target=\"_blank\">GSAT</a> <font color='red'>-3.1%</font>) has <a href=\"https://seekingalpha.com/pr/16966190-globalstar-announces-completion-public-offering-voting-common-stock\" target=\"_blank\">closed a public offering</a> of just over 73.36M shares of its voting common stock.</li>    <li>The company sold the shares at $1.65 each; <a href='https://seekingalpha.com/symbol/GSAT' title='Globalstar, Inc.'>GSAT</a> closed at $1.55 today and is flat in after-hours trading.</li>    <li>Aggregate net proceeds came to about $114.8M, 80% of which will be deposited in a restricted account for the benefit of lenders, and drawn to pay principal and interest due in December and June.</li>    <li>The rest will be used for general purposes.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300557\" data-linked=\"Globalstar closes 73.4M-share public offering\" data-tweet=\"$GSAT - Globalstar closes 73.4M-share public offering https://seekingalpha.com/news/3300557-globalstar-closes-73_4m-share-public-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3300557-globalstar-closes-73_4m-share-public-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300550\" data-ts=\"1507755336\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRK\" target=\"_blank\">MRK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300550-merck-bails-on-cholesterol-med-anacetrapib-no-regulatory-applications-planned-shares-down-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Merck bails on cholesterol med anacetrapib, no regulatory applications planned; shares down 1% after hours</a></h4><ul><li>Merck (NYSE:<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a>) is down&nbsp;<font color='red'>1%</font>&nbsp;after hours on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16966205-merck-provides-update-anacetrapib-development-program\" target=\"_blank\">announcement </a>that it will not file regulatory applications for cholesterol candidate anacetrapib saying its efficacy profile does not support the action.</li><li>The company joins Lilly (NYSE:<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a>), Roche (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a>) and Pfizer (NYSE:<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a>) in abandoning its program.</li><li>Anacetrapib inhibits a protein called cholesterol ester transfer protein &#40;CETP&#41;, which is designed to elevate HDL cholesterol (the \"good\" cholesterol). CETP inhibitors were all the rage a few years ago over their potential to provide more cardioprotective benefits than lowering LDL cholesterol (the \"bad\" cholesterol). Big Pharma's efforts to push CETP inhibitors over the finish line fell flat due to toxicity and less-than-expected efficacy.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3275700-mercks-anacetrapib-reduced-incidence-major-coronary-events-high-risk-patients-large-scale\" target=\"_blank\">Merck's anacetrapib reduced incidence of major coronary events in high-risk patients in large-scale study; shares ahead 2% premarket</a> (June 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3300550\" data-linked=\"Merck bails on cholesterol med anacetrapib, no regulatory applications planned; shares down 1% after hours\" data-tweet=\"$MRK $MRK $LLY - Merck bails on cholesterol med anacetrapib, no regulatory applications planned; shares down 1% after hours https://seekingalpha.com/news/3300550-merck-bails-on-cholesterol-med-anacetrapib-no-regulatory-applications-planned-shares-down-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3300550-merck-bails-on-cholesterol-med-anacetrapib-no-regulatory-applications-planned-shares-down-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300547\" data-ts=\"1507754890\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADMA\" target=\"_blank\">ADMA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300547-adma-readies-equity-offering-sminus-1-filed-shares-up-1-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ADMA readies equity offering, S-1 filed; shares up 1% after hours</a></h4><ul><li>ADMA Biologics (NASDAQ:<a href='https://seekingalpha.com/symbol/ADMA' title='ADMA Biologics Inc'>ADMA</a>) files an <a href=\"https://www.sec.gov/Archives/edgar/data/1368514/000119380517003279/e617359_s1-adma.htm\" target=\"_blank\">S-1 </a>for a $28.75M public offering of common stock. Price, volume and terms have yet to be released.</li><li>Shares are up&nbsp;<font color='green'>1%</font>&nbsp;after hours on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300547\" data-linked=\"ADMA readies equity offering, S-1 filed; shares up 1% after hours\" data-tweet=\"$ADMA - ADMA readies equity offering, S-1 filed; shares up 1% after hours https://seekingalpha.com/news/3300547-adma-readies-equity-offering-sminus-1-filed-shares-up-1-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3300547-adma-readies-equity-offering-sminus-1-filed-shares-up-1-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:48 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300536\" data-ts=\"1507754486\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTGX\" target=\"_blank\">PTGX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300536-protagonist-readies-equity-offering-shares-up-1-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Protagonist readies equity offering; shares up 1% after hours</a></h4><ul><li>Thinly traded micro cap Protagonist Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTGX' title='Protagonist Therapeutics'>PTGX</a>) is up&nbsp;<font color='green'>1%</font>&nbsp;after hours on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/16966101-protagonist-therapeutics-announces-proposed-public-offering-common-stock\" target=\"_blank\">announced </a>public offering of common stock. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300536\" data-linked=\"Protagonist readies equity offering; shares up 1% after hours\" data-tweet=\"$PTGX - Protagonist readies equity offering; shares up 1% after hours https://seekingalpha.com/news/3300536-protagonist-readies-equity-offering-shares-up-1-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3300536-protagonist-readies-equity-offering-shares-up-1-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:41 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300533\" data-ts=\"1507754251\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NSTG\" target=\"_blank\">NSTG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300533-nanostring-q3-top-line-reach-27m-product-service-revenue-below-guidance-shares-down-10-after\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NanoString Q3 top line could reach $27M, but product/service revenue below guidance; shares down 10% after hours</a></h4><ul><li>On a <a href=\"https://seekingalpha.com/pr/16966103-nanostring-announces-preliminary-revenue-third-quarter-fiscal-year-2017\" target=\"_blank\">preliminary basis</a>, NanoString Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/NSTG' title='NanoString Technologies'>NSTG</a>) expects Q3 revenues of $25.9M - 26.9M, including ~$16.9M in product and service revenue, short of its guidance of $19.5M - 21.5M.</li><li>CEO Brad Gray says, \"We are in the process of transforming our business, by strengthening our commercial channel to drive growth on an increasing scale, while setting the stage for the launch of multiple innovative products currently in development. While we are disappointed that softness in our instrument and consumable sales drove a shortfall in our product and service revenue in the third quarter, we believe that initiatives underway will strengthen the value proposition of our products and enhance the growth of the business over time.&rdquo;</li><li>Detailed Q3 results will be released on November 2 after the close.</li><li>2017 revenue guidance was $114M - 118M in July.</li><li>Shares are down&nbsp;<font color='red'>10%</font>&nbsp;after hours on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300533\" data-linked=\"NanoString Q3 top line could reach $27M, but product/service revenue below guidance; shares down 10% after hours\" data-tweet=\"$NSTG - NanoString Q3 top line could reach $27M, but product/service revenue below guidance; shares down 10% after hours https://seekingalpha.com/news/3300533-nanostring-q3-top-line-reach-27m-product-service-revenue-below-guidance-shares-down-10-after?source=tweet\" data-url=\"https://seekingalpha.com/news/3300533-nanostring-q3-top-line-reach-27m-product-service-revenue-below-guidance-shares-down-10-after\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:37 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300526\" data-ts=\"1507753698\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JILL\" target=\"_blank\">JILL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300526-j-jill-lowers-q3-guidance-sharesminus-14-ah\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">J.Jill lowers Q3 guidance; shares -14% AH</a></h4><ul>     <li>J.Jill (NYSE:<a href='https://seekingalpha.com/symbol/JILL' title='J. Jill Group, Inc.'>JILL</a>) <a href=\"https://seekingalpha.com/pr/16966156-j-jill-inc-updates-q3-fiscal-2017-guidance\" target=\"_blank\">now expects</a>&nbsp;Q3 total comparable sales of -3% to -5%, with a moderate decline in GM as compared to last year.</li>     <li>The company expects&nbsp;GAAP diluted EPS of $0.07 - $0.09.</li>     <li>Adjusted diluted EPS of&nbsp;<font color='red'>$0.08 - $0.10</font>&nbsp;vs. a consensus of $0.19.</li>     <li>President and CEO, Paula Bennett: \"We have experienced a lower than expected sales trend across both our retail and direct channels, and are updating our guidance for the quarter. We have been assessing the change in trend and have identified product and marketing calendar issues that are affecting traffic and conversion, and we are reacting quickly.&rdquo;</li>     <li>The company will provide its outlook for the Q4 and a revised outlook for the FY2017 when it reports Q3 results on Dec. 5th.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300526\" data-linked=\"J.Jill lowers Q3 guidance; shares -14% AH\" data-tweet=\"$JILL - J.Jill lowers Q3 guidance; shares -14% AH https://seekingalpha.com/news/3300526-j-jill-lowers-q3-guidance-sharesminus-14-ah?source=tweet\" data-url=\"https://seekingalpha.com/news/3300526-j-jill-lowers-q3-guidance-sharesminus-14-ah\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:28 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300525\" data-ts=\"1507753682\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JNPR\" target=\"_blank\">JNPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300525-juniper-networksminus-4_1-preliminary-q3-numbers-fall-short\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Juniper Networks -4.1% as preliminary Q3 numbers fall short</a></h4><ul>   <li>Juniper Networks (<a href=\"http://seekingalpha.com/symbol/JNPR\" target=\"_blank\">JNPR</a> <font color='red'>-1.7%</font>) is <font color='red'>off 4.1%</font> in postmarket trading after the company posted <a href=\"https://seekingalpha.com/pr/16966138-juniper-networks-announces-preliminary-third-quarter-2017-financial-results-date-conference\" target=\"_blank\">preliminary Q3 results lower than expected</a>, due to a disappointing cloud vertical.</li>    <li>Revenue for Q3 is expected at $1.25B-$1.26B, down from a previous forecast for $1.29B-$1.35B (and vs. Street consensus for $1.326B).</li>    <li>It now sees non-GAAP EPS of $0.54-$0.56, below previous guidance for $0.55-$0.61 and vs. consensus for $0.58.</li>    <li>The company's full results will come Oct. 24 after the close, followed by a conference call at 5 p.m. ET that day.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300525\" data-linked=\"Juniper Networks -4.1% as preliminary Q3 numbers fall short\" data-tweet=\"$JNPR - Juniper Networks -4.1% as preliminary Q3 numbers fall short https://seekingalpha.com/news/3300525-juniper-networksminus-4_1-preliminary-q3-numbers-fall-short?source=tweet\" data-url=\"https://seekingalpha.com/news/3300525-juniper-networksminus-4_1-preliminary-q3-numbers-fall-short\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300524\" data-ts=\"1507753658\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRVN\" target=\"_blank\">TRVN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300524-trevena-to-restructure-cut-30-of-workforce-shares-down-12-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trevena to restructure, cut 30% of workforce; shares down 12% after hours</a></h4><ul><li>With the aim of focusing resources on the approval and commercialization of pain med OLINVO (oliceridine injection), Trevena (NASDAQ:<a href='https://seekingalpha.com/symbol/TRVN' title='Trevena, Inc.'>TRVN</a>) will <a href=\"https://seekingalpha.com/pr/16966100-trevena-announces-restructuring-focus-resources-commercial-strategy\" target=\"_blank\">restructure </a>and revise its strategy.</li><li>It will cease investing in early-stage research, but will complete the ongoing Phase 1 study of migraine candidate TRV250. Once completed, it will evaluate its options for the asset as well as its lineup of S1P modulators for neuropathic pain.</li><li>The restructuring involves the elimination of 21 full-time positions or 30% of its headcount, mostly from research. The company expects the cuts to reduce operating expenses by $40M over the next three years. It will record a $2M charge this quarter related to the action.</li><li>Management expects to file its U.S. marketing application for OLINVO this month.</li><li>Trading will resume momentarily.</li><li><strong>Update</strong>: Shares are down&nbsp;<font color='red'>12%&nbsp;</font>after hours on robust volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300524\" data-linked=\"Trevena to restructure, cut 30% of workforce; shares down 12% after hours\" data-tweet=\"$TRVN - Trevena to restructure, cut 30% of workforce; shares down 12% after hours https://seekingalpha.com/news/3300524-trevena-to-restructure-cut-30-of-workforce-shares-down-12-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3300524-trevena-to-restructure-cut-30-of-workforce-shares-down-12-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300520\" data-ts=\"1507753014\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARDX\" target=\"_blank\">ARDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300520-ardelyxs-tenapanor-successful-in-second-late-stage-ibs-c-study-shares-ahead-57-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ardelyx&#39;s tenapanor successful in second late-stage IBS-C study; shares ahead 57% after hours</a></h4><ul><li>Ardelyx (NASDAQ:<a href='https://seekingalpha.com/symbol/ARDX' title='Ardelyx'>ARDX</a>) <a href=\"https://seekingalpha.com/pr/16966104-ardelyxs-pivotal-phase-3-study-tenapanor-ibs-c-hits-primary-secondary-endpoints-support-nda\" target=\"_blank\">announces </a>positive results from a second Phase 3 clinical trial, T3MPO-2, assessing tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C). The study met its primary endpoint and all secondary endpoints.</li><li>The primary endpoint was the combined responder rate for six and 12 weeks versus placebo (36.5% vs. 23.7%; p&lt;0.001).</li><li>On the safety front, tenapanor was well-tolerated but the incidence of diarrhea was 16.0%, a bit higher than the first Phase 3 study (14.6%).</li><li>The company expects to file its U.S. marketing application in H2 2018.</li><li>Management will host a conference call today at 4:30 pm ET to discuss the results.</li><li>Trading will resume at 4:30 pm ET.</li><li><strong>Update</strong>: Shares are up&nbsp;<font color='green'>57%</font>&nbsp;after hours on robust volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300520\" data-linked=\"Ardelyx&#39;s tenapanor successful in second late-stage IBS-C study; shares ahead 57% after hours\" data-tweet=\"$ARDX - Ardelyx&#39;s tenapanor successful in second late-stage IBS-C study; shares ahead 57% after hours https://seekingalpha.com/news/3300520-ardelyxs-tenapanor-successful-in-second-late-stage-ibs-c-study-shares-ahead-57-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3300520-ardelyxs-tenapanor-successful-in-second-late-stage-ibs-c-study-shares-ahead-57-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300518\" data-ts=\"1507752892\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XPER\" target=\"_blank\">XPER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300518-xperi-shares-plunge-on-patent-fight-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Xperi shares plunge on patent fight update</a></h4><ul><li>        Xperi (NASDAQ:<a href='https://seekingalpha.com/symbol/XPER' title='Xperi Corporation'>XPER</a>) shares close today&nbsp;<font color='red'>down 13.95%&nbsp;</font>after the company <a href=\"https://seekingalpha.com/pr/16966028-invensas-gives-update-german-legal-proceedings-broadcom\" target=\"_blank\">updates</a> its legal proceedings against Broadcom (NASDAQ:<a href='https://seekingalpha.com/symbol/AVGO' title='Broadcom Limited'>AVGO</a>).</li><li>               The German Federal Patent Court says the patent Broadcom was accused of infringing might be invalid &ldquo;for various reasons.&rdquo;&nbsp;</li><li>               The Court&rsquo;s statement wasn&rsquo;t the final decision but a remark ahead of a January 25 hearing.&nbsp;</li><li>               Xperi&rsquo;s subsidiary Invensas will submit a response to the Court on December 6. &nbsp;&nbsp;</li><li>               &ldquo;We think the Court's reasoning in its preliminary statement is flawed, and we look forward to having the opportunity to provide further briefing and arguments at the hearing in January,&rdquo;&nbsp;says CEO Jon Kirchner.&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3300518\" data-linked=\"Xperi shares plunge on patent fight update\" data-tweet=\"$XPER $XPER $AVGO - Xperi shares plunge on patent fight update https://seekingalpha.com/news/3300518-xperi-shares-plunge-on-patent-fight-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3300518-xperi-shares-plunge-on-patent-fight-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300514\" data-ts=\"1507752280\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARDX\" target=\"_blank\">ARDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300514-trading-in-trevena-and-ardelyx-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trading in Trevena and Ardelyx halted pending news</a></h4><ul><li>Nasdaq has&nbsp;<a href=\"http://www.nasdaqtrader.com/trader.aspx?id=tradehalts\" target=\"_blank\">suspended </a>trading in Ardelyx (NASDAQ:<a href='https://seekingalpha.com/symbol/ARDX' title='Ardelyx'>ARDX</a>) and Trevena (NASDAQ:<a href='https://seekingalpha.com/symbol/TRVN' title='Trevena, Inc.'>TRVN</a>) pending the release of news.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300514\" data-linked=\"Trading in Trevena and Ardelyx halted pending news\" data-tweet=\"$ARDX $ARDX $TRVN - Trading in Trevena and Ardelyx halted pending news https://seekingalpha.com/news/3300514-trading-in-trevena-and-ardelyx-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3300514-trading-in-trevena-and-ardelyx-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300511\" data-ts=\"1507751783\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CIE\" target=\"_blank\">CIE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300511-cobalt-energy-gets-nyse-continued-listing-standard-notice\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cobalt Energy gets NYSE continued listing standard notice</a></h4><ul>     <li>Cobalt International Energy (<a href='https://seekingalpha.com/symbol/CIE' title='Cobalt International Energy, Inc.'>CIE</a> <font color='red'>-3.4%</font>) slumps to a new record low of $1.10 after saying it was warned by the NYSE that it is no longer in compliance with continued listing standards <a href=\"http://www.businesswire.com/news/home/20171011005349/en/Cobalt-International-Energy-Receives-Continued-Listing-Standard\" target=\"_blank\">and could be delisted</a> because the overall value of its shares has dropped below the exchange's $50M minimum market cap threshold.</li>     <li>CIE says it plans to submit a business plan to the NYSE within 45 days detailing its plan to return to compliance within the next six months.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300511\" data-linked=\"Cobalt Energy gets NYSE continued listing standard notice\" data-tweet=\"$CIE - Cobalt Energy gets NYSE continued listing standard notice https://seekingalpha.com/news/3300511-cobalt-energy-gets-nyse-continued-listing-standard-notice?source=tweet\" data-url=\"https://seekingalpha.com/news/3300511-cobalt-energy-gets-nyse-continued-listing-standard-notice\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:56 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300505\" data-ts=\"1507750418\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CARG\" target=\"_blank\">CARG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300505-auto-retail-sector-jittery-ahead-of-cargurus-ipo-pricing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Auto retail sector jittery ahead of Cargurus IPO pricing</a></h4><ul><li>A weak day for auto retailers is being attributed by Bloomberg to the upcoming pricing of the Cargurus.com (NASDAQ:<a href='https://seekingalpha.com/symbol/CARG' title='CarGurus, Inc.'>CARG</a>) IPO. Investors appear edgy that the IPO pricing may come in below expectations.</li><li>Cargurus is offering 9.4M shares in an expected range of $13 to $15.</li><li>It's a down day overall for retail, but AutoNation (<a href='https://seekingalpha.com/symbol/AN' title='AutoNation Inc'>AN</a> <font color='red'>-2.4%</font>), Advance Auto Parts (<a href='https://seekingalpha.com/symbol/AAP' title='Advance Auto Parts, Inc.'>AAP</a> <font color='red'>-2.4%</font>), Sonic Automotive (<a href='https://seekingalpha.com/symbol/SAH' title='Sonic Automotive Inc.'>SAH</a> <font color='red'>-3.2%</font>), Lithia Motors (<a href='https://seekingalpha.com/symbol/LAD' title='Lithia Motors, Inc.'>LAD</a> <font color='red'>-2.1%</font>) and Asbury Automotive (<a href='https://seekingalpha.com/symbol/ABG' title='Asbury Automotive Group, Inc.'>ABG</a> <font color='red'>-2.7%</font>) trade even weaker than sector averages.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3295891-cargurus-files-initial-public-offering\" target=\"_blank\">CarGurus files for initial public offering</a> (Sept. 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3300505\" data-linked=\"Auto retail sector jittery ahead of Cargurus IPO pricing\" data-tweet=\"$CARG $CARG $AN - Auto retail sector jittery ahead of Cargurus IPO pricing https://seekingalpha.com/news/3300505-auto-retail-sector-jittery-ahead-of-cargurus-ipo-pricing?source=tweet\" data-url=\"https://seekingalpha.com/news/3300505-auto-retail-sector-jittery-ahead-of-cargurus-ipo-pricing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300503\" data-ts=\"1507750052\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORPN\" target=\"_blank\">ORPN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300503-bioblast-pharma-up-65-on-european-patent\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bioblast Pharma up 65% on European patent</a></h4><ul><li>Thinly traded nano cap Bioblast Pharma (<a href='https://seekingalpha.com/symbol/ORPN' title='Bio Blast Pharma'>ORPN</a> <font color='green'>+65.4%</font>) is yet another tiny biotech showing bullish action. Shares are up on almost an 11x surge in volume, albeit on turnover of only 213K shares, in apparent response to a new <a href=\"https://register.epo.org/application?number=EP14723894\" target=\"_blank\">European patent</a> covering the construction and uses of mitochondrial proteins.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300503\" data-linked=\"Bioblast Pharma up 65% on European patent\" data-tweet=\"$ORPN $ENLV - Bioblast Pharma up 65% on European patent https://seekingalpha.com/news/3300503-bioblast-pharma-up-65-on-european-patent?source=tweet\" data-url=\"https://seekingalpha.com/news/3300503-bioblast-pharma-up-65-on-european-patent\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300504\" data-ts=\"1507749782\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VOXX\" target=\"_blank\">VOXX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300504-post-earnings-slump-for-voxx-international\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Post-earnings slump for VOXX International</a></h4><ul>     <li>VOXX International (<a href='https://seekingalpha.com/symbol/VOXX' title='VOXX International Corp.'>VOXX</a> <font color='red'>-20.9%</font>) slumps after the company's FQ2 earnings fall short.</li>     <li>Sales in the automotive segment sales fell 16% to $33M during the quarter.</li><li>Gross margin fell 240 bps to 25.0% of sales.</li><li>The company says higher marketing and advertising costs were realized in the quarter.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3300276-voxx-international-reports-q2-results\" target=\"_blank\">VOXX International reports Q2 results</a> (Oct. 10)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300504\" data-linked=\"Post-earnings slump for VOXX International\" data-tweet=\"$VOXX - Post-earnings slump for VOXX International https://seekingalpha.com/news/3300504-post-earnings-slump-for-voxx-international?source=tweet\" data-url=\"https://seekingalpha.com/news/3300504-post-earnings-slump-for-voxx-international\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300502\" data-ts=\"1507749494\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLB\" target=\"_blank\">SLB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300502-schlumberger-downgraded-bmo-2018-estimates-risk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Schlumberger downgraded at BMO as 2018 estimates at risk</a></h4><ul>     <li>Schlumberger (<a href='https://seekingalpha.com/symbol/SLB' title='Schlumberger Limited'>SLB</a> <font color='red'>-1.5%</font>) is <a href=\"http://www.barrons.com/articles/schlumberger-the-slump-will-continue-1507732039\" target=\"_blank\">downgraded</a> to Market Perform from Outperform with a $72 price target, trimmed from $74, at BMO Capital, which says the stock is trading above its historical levels on a forward EBITDA basis.</li>     <li>BMO says SLB's near-term growth is being driven by pressure pumping - which the firm says deserves a lower multiple - investments in project management are raising the company's capital intensity relative to peers, and recent events in Ecuador highlight the risk of host governments renegotiating.</li>     <li>The firm foresees risk to consensus earnings estimates for 2018 and believe the stock will have difficulty expanding its multiple but that SLB will still maintain its attractiveness as a defensive stock.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300502\" data-linked=\"Schlumberger downgraded at BMO as 2018 estimates at risk\" data-tweet=\"$SLB - Schlumberger downgraded at BMO as 2018 estimates at risk https://seekingalpha.com/news/3300502-schlumberger-downgraded-bmo-2018-estimates-risk?source=tweet\" data-url=\"https://seekingalpha.com/news/3300502-schlumberger-downgraded-bmo-2018-estimates-risk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300500\" data-ts=\"1507748608\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KTOV\" target=\"_blank\">KTOV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300500-kitov-pharma-latest-biotech-breakout-shares-up-37\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kitov Pharma latest biotech breakout, shares up 37%</a></h4><ul><li>Thinly traded nano cap Kitov Pharmaceuticals Holdings (<a href='https://seekingalpha.com/symbol/KTOV' title='Kitov Pharma Ltd.'>KTOV</a> <font color='green'>+36.6%</font>) joins the ever-growing list of biotech breakouts on more than an 18x surge in volume. No particular news accounts for the action.</li><li>Last week the company announced an additional 27% stake in TyrNovo with promising cancer candidate NT219 and the submission of its U.S. marketing application for combo med <a href=\"http://kitovpharma.com/products-2/kit-302/\" target=\"_blank\">KIT-302</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299750-kitov-ups-stake-oncology-focused-tyrnovo-92-percent-shares-ahead-9-percent-premarket\" target=\"_blank\">Kitov ups stake in oncology-focused TyrNovo to 92%; shares ahead 9% premarket</a> (Oct. 6)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298636-kitov-files-u-s-marketing-application-lead-candidate-kitminus-302-shares-ahead-8-percent\" target=\"_blank\">Kitov files U.S. marketing application for lead candidate KIT-302; shares ahead 8% premarket</a> (Oct. 2)</li></ul><div class=\"tiny-share-widget\" data-id=\"3300500\" data-linked=\"Kitov Pharma latest biotech breakout, shares up 37%\" data-tweet=\"$KTOV - Kitov Pharma latest biotech breakout, shares up 37% https://seekingalpha.com/news/3300500-kitov-pharma-latest-biotech-breakout-shares-up-37?source=tweet\" data-url=\"https://seekingalpha.com/news/3300500-kitov-pharma-latest-biotech-breakout-shares-up-37\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300499\" data-ts=\"1507748196\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300499-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> WPCS <font color='green'>+35%</font>. <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/MTBC' title='Medical Transcription Billing'>MTBC</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a> <font color='green'>+15%</font>. IFON <font color='green'>+15%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/NETE' title='Net Element International, Inc.'>NETE</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/RNVA' title='Rennova Health, Inc.'>OTCPK:RNVA</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/XPER' title='Xperi Corporation'>XPER</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/CUDA' title='Barracuda Networks, Inc'>CUDA</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/SITO' title='SITO Mobile, Ltd.'>SITO</a> <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300499\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$DCAR $HMNY $MTBC - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3300499-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3300499-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300493\" data-ts=\"1507747334\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ET\" target=\"_blank\">ET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300493-dakota-access-pipeline-ok-to-keep-running-during-study-judge-rules\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dakota Access pipeline OK to keep running during study, judge rules</a></h4><ul><li>Energy Transfer Partners (ETP <font color='green'>+1.6%</font>) moves higher after a federal judge rules that the Dakota Access pipeline can  <a href=\"https://apnews.com/9cdf9c3cd434433e97b53fb2f9a3ecf1\" target=\"_blank\">continue operating</a> while a study is completed to assess its  environmental impact.</li><li>The decision is a blow to the Standing Rock Sioux tribe, who have argued  that an oil spill from the pipeline under the Lake Oahe reservoir in the Dakotas could have a detrimental effect on the tribal  community.</li><li>The judge had ruled in June that the Army Corps of Engineers had largely complied with environmental law  but that it had not adequately considered how an  oil spill under Lake Oahe might affect the tribe, and he took arguments on whether to shut down the 1,200-mile pipeline while the work was done.</li><li>ETP had maintained that a shutdown would cost it $90M/month and  significantly disrupt the broader energy industry as well as state and  local government tax revenue.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300493\" data-linked=\"Dakota Access pipeline OK to keep running during study, judge rules\" data-tweet=\"$ET - Dakota Access pipeline OK to keep running during study, judge rules https://seekingalpha.com/news/3300493-dakota-access-pipeline-ok-to-keep-running-during-study-judge-rules?source=tweet\" data-url=\"https://seekingalpha.com/news/3300493-dakota-access-pipeline-ok-to-keep-running-during-study-judge-rules\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>184&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300489\" data-ts=\"1507747117\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300489-strong-demand-seen-10-year-treasury-auction\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Strong demand seen at 10-year Treasury auction</a></h4><ul><li>Taking advantage of the sharply higher yield on the 10-year Treasury over the past month, real-money buyers took down a full 69% of today's $20B auction vs. 55% at the last sale (yield today was 2.35% vs. 2.18% at the last one).</li><li>Dealers needed to buy up just 25% of today's sale vs. 39% at the last one.</li><li>Thomas Byrne from Wealth Strategies &amp; Management <a href=\"http://www.barrons.com/articles/market-hungry-for-10-year-treasuries-yielding-2-3-1507743347?mod=hp_RTA&amp;\" target=\"_blank\">tells <em>Barron's</em> that</a> such strong demand may be a sign that the rise in yields is about over.</li><li>The 10-year yield is down 2 basis points today to 2.34%. <a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>&nbsp;<font color='green'>+0.25%</font>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>&nbsp;<font color='red'>-0.5%</font></li><li>Previously: <a href=\"https://seekingalpha.com/news/3300479-hoisington-management-remains-bullish-treasurys\" target=\"_blank\">Hoisington Management remains bullish on Treasurys</a> (Oct. 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3300489\" data-linked=\"Strong demand seen at 10-year Treasury auction\" data-tweet=\"$TLT $TBT - Strong demand seen at 10-year Treasury auction https://seekingalpha.com/news/3300489-strong-demand-seen-10-year-treasury-auction?source=tweet\" data-url=\"https://seekingalpha.com/news/3300489-strong-demand-seen-10-year-treasury-auction\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:38 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300488\" data-ts=\"1507746846\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIVHY\" target=\"_blank\">VIVHY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300488-italy-party-chief-mulls-state-role-for-telecom-italia\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Italy party chief mulls state role for Telecom Italia</a></h4><ul>   <li>Italy's ruling party has a solution for the dispute between the country and France's Vivendi (<a href=\"http://seekingalpha.com/symbol/VIVHY\" target=\"_blank\">VIVHY</a> <font color='red'>-0.1%</font>) over the latter's moves to take control of key Italian companies: Moving strategic companies such as Telecom Italia (<a href=\"http://seekingalpha.com/symbol/TI\" target=\"_blank\">TI</a> <font color='green'>+2.1%</font>) into <a href=\"https://finance.yahoo.com/news/italy-state-role-t-italia-123345605.html\" target=\"_blank\">more of a state-owned role</a>.</li>    <li>Matteo Orfini, president of the ruling PD party (but not a government official), published a position paper suggesting that state lender Cassa Depositi e Prestiti could be involved in transferring TIM's network to a state-owned entity.</li>    <li>That eliminates infrastructure rivalry that's \"unsustainable in the long term,\" he says.</li>    <li>Similar suggestions to spin off a business estimated as worth up to &euro;15B have failed in the past over valuation questions and TIM's insistence on hanging on to the business.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3300243-reports-vivendi-offering-payment-settle-mediaset-dispute\" target=\"_blank\">Reports: Vivendi offering payment to settle Mediaset dispute</a> (Oct. 10 2017)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298308-reuters-italy-beginning-steps-fine-vivendi\" target=\"_blank\">Reuters: Italy beginning steps to fine Vivendi</a> (Sep. 28 2017)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3295473-vivendi-appealing-italy-ruling-controls-telecom-italia\" target=\"_blank\">Vivendi appealing Italy ruling that it controls Telecom Italia</a> (Sep. 14 2017)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300488\" data-linked=\"Italy party chief mulls state role for Telecom Italia\" data-tweet=\"$VIVHY $VIVHY $TI - Italy party chief mulls state role for Telecom Italia https://seekingalpha.com/news/3300488-italy-party-chief-mulls-state-role-for-telecom-italia?source=tweet\" data-url=\"https://seekingalpha.com/news/3300488-italy-party-chief-mulls-state-role-for-telecom-italia\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:34 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300481\" data-ts=\"1507744854\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300481-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PVG' title='Pretium Resources Inc'>PVG</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/VHI' title='Valhi, Inc.'>VHI</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/CMC' title='Commercial Metals Company'>CMC</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/NRP' title='Natural Resource Partners LP'>NRP</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/USAP' title='Universal Stainless & Alloy Products, Inc.'>USAP</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ODC' title='Oil Dri Corporation of America'>ODC</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/USEG' title='U.S. Energy Corp.'>USEG</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/UEC' title='Uranium Energy Corp'>UEC</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/EPE' title='EP Energy Corporation'>EPE</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300481\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$PVG $VHI $CMC - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3300481-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3300481-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300581\" data-ts=\"1507744689\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GST\" target=\"_blank\">GST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300581-gastar-exploration-cuts-q3-fy-2017-production-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gastar Exploration cuts Q3, FY 2017 production guidance</a></h4><ul>     <li>Gastar Exploration (<a href='https://seekingalpha.com/symbol/GST' title='Gastar Exploration Inc.'>GST</a> <font color='red'>-4.1%</font>)&nbsp;is lower after <a href=\"https://seekingalpha.com/pr/16965158-gastar-exploration-updates-third-quarter-full-year-2017-production-guidance\" target=\"_blank\">cutting Q3 and FY 2017 production guidance</a>, resulting from operational challenges the company believes have been resolved.</li>     <li>GST says it expects to report Q3 production of 6.1K-6.3K boe/day, down from prior guidance of 6.3K-6.8K boe/day, and full-year production of 6K-6.4K boe/day, down from its previous outlook for 6.2K-6.8K boe/day.</li><li>GST offers no details on the nature of the operational issues but will provide a more comprehensive update in its Q3 earnings call.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300581\" data-linked=\"Gastar Exploration cuts Q3, FY 2017 production guidance\" data-tweet=\"$GST - Gastar Exploration cuts Q3, FY 2017 production guidance https://seekingalpha.com/news/3300581-gastar-exploration-cuts-q3-fy-2017-production-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3300581-gastar-exploration-cuts-q3-fy-2017-production-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300480\" data-ts=\"1507743650\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MA\" target=\"_blank\">MA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300480-wells-fargo-positive-on-visa-and-mastercard\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wells Fargo positive on Visa and Mastercard</a></h4><ul><li>Wells Fargo picks coverage back up on Mastercard (<a href='https://seekingalpha.com/symbol/MA' title='Mastercard, Inc.'>MA</a> <font color='green'>+0.5%</font>) and Visa (<a href='https://seekingalpha.com/symbol/V' title='Visa Inc.'>V</a> <font color='green'>+1%</font>) with <a href=\"https://www.streetinsider.com/Analyst+Comments/Wells+Fargo+Upgrades+MasterCard+%28MA%29+to+Outperform/13378692.html\" target=\"_blank\">Outperform ratings</a> on a \"constructive\" outlook on the payments sector.</li><li>Mastercard earns a price target of $160 from Wells to rep 10% upside potential.</li><li>Visa catches a price target of $120 to rep 11% upside potential.</li><li>Mastercard is already up 42% YTD, while Visa is 39% higher.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300480\" data-linked=\"Wells Fargo positive on Visa and Mastercard\" data-tweet=\"$MA $MA $V - Wells Fargo positive on Visa and Mastercard https://seekingalpha.com/news/3300480-wells-fargo-positive-on-visa-and-mastercard?source=tweet\" data-url=\"https://seekingalpha.com/news/3300480-wells-fargo-positive-on-visa-and-mastercard\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300477\" data-ts=\"1507742926\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOX\" target=\"_blank\">FOX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300477-fox-sells-off-u-s-world-cup-failure-dims-broadcast-hype\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fox sells off as U.S. World Cup failure dims broadcast hype</a></h4><ul>   <li>Fox Sports (<a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a> <font color='red'>-2.6%</font>, <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a> <font color='red'>-2.5%</font>) is putting on a brave face, but a stunning failure of the U.S. men's national soccer team to make the 2018 World Cup is weighing heavily on shares today.</li><li>Volume in the company's A&nbsp;shares is running well above daily average at close to 10M shares.</li>    <li>The broadcaster paid $425M for U.S. rights to broadcast the FIFA World Cups from 2015-2022; next year, it will do it without the huge draw of the American men.</li>    <li>The men's team lost to Trinidad and Tobago 2-1 last night in what's termed as the most embarrassing defeat in U.S. soccer history. The team was eliminated from World Cup qualifying for the first time since the 1986 cycle.</li>    <li>It's still the \"greatest sporting event on earth,\" Fox says. &ldquo;Last night&rsquo;s World Cup qualifying results do not change Fox Sports&rsquo; passion for the world&rsquo;s biggest sporting event. While the U.S. was eliminated, the biggest stars in the world from Lionel Messi to Cristiano Ronaldo stamped their tickets to Russia on the same day, and will battle teams ranging from Mexico to England that have massive fan bases in America.&rdquo;</li>    <li>Fox had <a href=\"http://www.adweek.com/tv-video/fall-tv-has-3-new-military-shows-but-buyers-think-only-2-have-a-chance-to-survive/\" target=\"_blank\">planned 350 hours of programming</a>, and now faces a significant ratings and advertising hit.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300477\" data-linked=\"Fox sells off as U.S. World Cup failure dims broadcast hype\" data-tweet=\"$FOX $FOX $FOXA - Fox sells off as U.S. World Cup failure dims broadcast hype https://seekingalpha.com/news/3300477-fox-sells-off-u-s-world-cup-failure-dims-broadcast-hype?source=tweet\" data-url=\"https://seekingalpha.com/news/3300477-fox-sells-off-u-s-world-cup-failure-dims-broadcast-hype\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>40&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300473\" data-ts=\"1507742127\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOX\" target=\"_blank\">FOX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300473-sky-pressed-to-honor-independent-wishes-on-fate-of-chairman-murdoch\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sky pressed to honor independent wishes on fate of Chairman Murdoch</a></h4><ul>   <li>British broadcaster Sky (<a href=\"http://seekingalpha.com/symbol/SKYAY\" target=\"_blank\">SKYAY</a> <font color='red'>-0.2%</font>) is under pressure from lobby group the Institute of Directors to <a href=\"https://finance.yahoo.com/news/sky-faces-pressure-over-murdoch-103402803.html\" target=\"_blank\">oust Chairman James Murdoch</a> if he's opposed by a majority of independent shareholders at the annual meeting this week.</li>    <li>Those investors hold just over 60% of the company. And proxy adviser ISS has urged voting against Murdoch, citing a conflict with his other role as CEO at Twenty-First Century Fox (<a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a> <font color='red'>-2.4%</font>, <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a> <font color='red'>-2.3%</font>), currently engaged in an &pound;11.7B bid to buy out the near-60% of Sky it doesn't own.</li>    <li>&ldquo;It would be very unconvincing if the board is forced to use the block vote of the Fox shareholder in order to back the re-appointment of James Murdoch,&rdquo; said governance expert Stefan Stern.</li>    <li>It's just the latest control-related spat having to do with the Murdoch family, which has faced down determined opposition at Fox and News Corp (<a href='https://seekingalpha.com/symbol/NWS' title='News Corporation'>NWS</a> <font color='red'>-0.9%</font>, <a href='https://seekingalpha.com/symbol/NWSA' title='News Corporation'>NWSA</a> <font color='red'>-0.7%</font>) in large part due to holding supervoting shares that retain control for the family.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300473\" data-linked=\"Sky pressed to honor independent wishes on fate of Chairman Murdoch\" data-tweet=\"$FOX $FOX $FOXA - Sky pressed to honor independent wishes on fate of Chairman Murdoch https://seekingalpha.com/news/3300473-sky-pressed-to-honor-independent-wishes-on-fate-of-chairman-murdoch?source=tweet\" data-url=\"https://seekingalpha.com/news/3300473-sky-pressed-to-honor-independent-wishes-on-fate-of-chairman-murdoch\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300472\" data-ts=\"1507741836\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PVG\" target=\"_blank\">PVG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300472-pretium-resourcesplus-22-on-strong-brucejack-mine-production\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pretium Resources +22% on strong Brucejack mine production</a></h4><ul>     <li>Pretium Resources (<a href='https://seekingalpha.com/symbol/PVG' title='Pretium Resources Inc'>PVG</a> <font color='green'>+22.3%</font>) soars more than 20% to a seven-month high after saying its Brucejack mine in British Columbia <a href=\"https://seekingalpha.com/pr/16965033-pretium-resources-inc-82203-ounces-gold-produced-brucejack-mine-q3-2017\" target=\"_blank\">produced 82.2K oz. of gold in Q3</a>, beating <a href=\"https://timesofindia.indiatimes.com/business/international-business/pretium-resources-inc-soars-on-brucejack-mine-q3-production/articleshow/61040651.cms\" target=\"_blank\">analyst estimates</a>.</li>     <li>Credit Suisse had expected production of 81K oz., while BMO analysts had forecast just 71K oz. and say they would be buyers of the stock on the news; citing the result, Scotiabank upgrades shares to Outperform from Sector Perform.</li>     <li>PVG says Q3 mill feed grade and gold recoveries averaged 10.52  grams/metric ton and 96.49%, respectively; during the last two months of the quarter, mill feed grade and gold  recoveries averaged 12.36 grams/metric ton gold and 96.92%, respectively, as the mill transitioned to processing stope ore exclusively.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300472\" data-linked=\"Pretium Resources +22% on strong Brucejack mine production\" data-tweet=\"$PVG - Pretium Resources +22% on strong Brucejack mine production https://seekingalpha.com/news/3300472-pretium-resourcesplus-22-on-strong-brucejack-mine-production?source=tweet\" data-url=\"https://seekingalpha.com/news/3300472-pretium-resourcesplus-22-on-strong-brucejack-mine-production\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300471\" data-ts=\"1507741578\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300471-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/FRSX' title='Foresight Autonomous Holdings Ltd.'>FRSX</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/CASH' title='Meta Financial Group, Inc.'>CASH</a> <font color='green'>+11%</font>.<a href='https://seekingalpha.com/symbol/TURN' title='180 Degree Capital Corp'>TURN</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/MLP' title='Maui Land & Pineapple Company, Inc.'>MLP</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/YRD' title='Yirendai LTD.'>YRD</a> <font color='green'>+5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300471\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$FRSX $CASH $TURN - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3300471-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3300471-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300470\" data-ts=\"1507741190\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMC\" target=\"_blank\">CMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300470-steel-stocks-surge-takeover-deal-takes-shape\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Steel stocks surge as takeover deal takes shape</a></h4><ul>     <li>Steel companies are surging across the board amid speculation that Commercial Metals (<a href='https://seekingalpha.com/symbol/CMC' title='Commercial Metals Company'>CMC</a> <font color='green'>+7.1%</font>) may purchase Gerdau&rsquo;s (<a href='https://seekingalpha.com/symbol/GGB' title='Gerdau S.A.'>GGB</a> <font color='red'>-1.4%</font>) North American rebar mills.</li>     <li>The speculation comes as the <a href=\"https://seekingalpha.com/news/3300061-steel-data-falsification-scandal-spreading-japanese-industry\" target=\"_blank\">scandal</a> engulfing Japan's Kobe Steel deepens, likely removing the company as a competitor for the time being, and Credit Suisse says GGB has been a $5-$10/ton drag on industry metal margins; another key factor could include the boost to steel profitability from flat iron ore prices and the declining cost of coal.</li>     <li><a href='https://seekingalpha.com/symbol/NUE' title='Nucor Corporation'>NUE</a> <font color='green'>+3.6%</font>, <a href='https://seekingalpha.com/symbol/SCHN' title='Schnitzer Steel Industries, Inc.'>SCHN</a> <font color='green'>+2.8%</font>, <a href='https://seekingalpha.com/symbol/STLD' title='Steel Dynamics, Inc.'>STLD</a> <font color='green'>+2.2%</font>, <a href='https://seekingalpha.com/symbol/ZEUS' title='Olympic Steel, Inc.'>ZEUS</a> <font color='green'>+2%</font>, <a href='https://seekingalpha.com/symbol/AKS' title='AK Steel Holding Corp'>AKS</a> <font color='green'>+1.8%</font>, <a href='https://seekingalpha.com/symbol/WOR' title='Worthington Industries, Inc.'>WOR</a> <font color='green'>+1.6%</font>, <a href='https://seekingalpha.com/symbol/TMST' title='TimkenSteel Corp.'>TMST</a> <font color='green'>+1.3%</font>, <a href='https://seekingalpha.com/symbol/RS' title='Reliance Steel & Aluminum Co.'>RS</a> <font color='green'>+1.2%</font>, <a href='https://seekingalpha.com/symbol/SXC' title='SunCoke Energy'>SXC</a> <font color='green'>+1.2%</font>, <a href='https://seekingalpha.com/symbol/X' title='United States Steel Corporation'>X</a> <font color='green'>+0.8%</font>, <a href='https://seekingalpha.com/symbol/MT' title='ArcelorMittal'>MT</a> <font color='green'>+0.5%</font>.</li>     <li>Source:&nbsp;Bloomberg First Word</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300470\" data-linked=\"Steel stocks surge as takeover deal takes shape\" data-tweet=\"$CMC $CMC $GGB - Steel stocks surge as takeover deal takes shape https://seekingalpha.com/news/3300470-steel-stocks-surge-takeover-deal-takes-shape?source=tweet\" data-url=\"https://seekingalpha.com/news/3300470-steel-stocks-surge-takeover-deal-takes-shape\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300467\" data-ts=\"1507740937\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DAL\" target=\"_blank\">DAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300467-delta-unit-revenue-outlook-called-watershed-event\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Delta unit revenue outlook called a &#39;watershed&#39; event</a></h4><ul><li>Cowen analyst Helane Becker calls the unit revenue guidance from Delta Air Lines (<a href='https://seekingalpha.com/symbol/DAL' title='Delta Air Lines, Inc.'>DAL</a> <font color='green'>+1%</font>) a \"watershed event\" for the company and the airline sector as a whole.</li><li>Becker thinks the solid outlook from Delta for 2% to 4% passenger revenue per available seat mile growth could bring investors back into airline stocks.</li><li>Cowen keeps an Outperform rating on Delta in place.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3300165-airlines-show-improved-margins-trend-despite-hurricanes\" target=\"_blank\">Airlines show improved margins trend despite hurricanes</a> (Oct. 10)</li><li>Related ETF: <a href='https://seekingalpha.com/symbol/JETS' title='U.S. Global Jets ETF'>JETS</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3300467\" data-linked=\"Delta unit revenue outlook called a &#39;watershed&#39; event\" data-tweet=\"$DAL $DAL $JETS - Delta unit revenue outlook called a &#39;watershed&#39; event https://seekingalpha.com/news/3300467-delta-unit-revenue-outlook-called-watershed-event?source=tweet\" data-url=\"https://seekingalpha.com/news/3300467-delta-unit-revenue-outlook-called-watershed-event\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>39&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300462\" data-ts=\"1507740050\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300462-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/LBIX-OLD' title='Leading Brands Inc'>LBIX-OLD</a> <font color='green'>+84%</font>. <a href='https://seekingalpha.com/symbol/CASI' title='CASI Pharmaceuticals'>CASI</a> <font color='green'>+71%</font>. <a href='https://seekingalpha.com/symbol/SRNE' title='Sorrento Therapeutics, Inc.'>SRNE</a> <font color='green'>+37%</font>. WPCS <font color='green'>+37%</font>. <a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a> <font color='green'>+34%</font>. <a href='https://seekingalpha.com/symbol/RGSE' title='RGS Energy, Inc.'>RGSE</a> <font color='green'>+34%</font>. <a href='https://seekingalpha.com/symbol/AMMA-OLD' title='Alliance MMA'>AMMA-OLD</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/FRSX' title='Foresight Autonomous Holdings Ltd.'>FRSX</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/PVG' title='Pretium Resources Inc'>PVG</a> <font color='green'>+20%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/VOXX' title='VOXX International Corp.'>VOXX</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/DGSE' title='DGSE Companies, Inc'>DGSE</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/CRY' title='CryoLife, Inc.'>CRY</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/KNDI' title='Kandi Technologies Group, Inc.'>KNDI</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/ODC' title='Oil Dri Corporation of America'>ODC</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/NETE' title='Net Element International, Inc.'>NETE</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/RNVA' title='Rennova Health, Inc.'>OTCPK:RNVA</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/XPER' title='Xperi Corporation'>XPER</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/CIDM' title='Cinedigm Corp.'>CIDM</a> <font color='red'>-13%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300462\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$LBIX-OLD $CASI $SRNE - Midday Gainers / Losers https://seekingalpha.com/news/3300462-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3300462-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300460\" data-ts=\"1507739058\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVDA\" target=\"_blank\">NVDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300460-goldman-sachs-ups-nvidias-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman Sachs ups Nvidia&#39;s price target</a></h4><ul><li>        Goldman Sachs increases its Nvidia (NASDAQ:<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a>) price target to $217 from $193 and maintains a Conviction Buy rating.</li><li>               Latest analyst standings on Nvidia: 10 Buy, 13 Outperform, 12 Hold, and 4 Underperform.&nbsp;</li><li>               Median price target: $180.&nbsp;</li><li>               Nvidia shares are&nbsp;<font color='green'>up 0.87%.</font>&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3300075-nvidia-unveils-new-self-driving-taxi-hardware\" target=\"_blank\">Nvidia unveils new self-driving taxi hardware</a> (Oct. 10)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3300242-nvidia-partners-announce-self-driving-delivery-truck-test-fleet\" target=\"_blank\">Nvidia, partners announce self-driving delivery truck test fleet</a> (Oct. 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3300460\" data-linked=\"Goldman Sachs ups Nvidia&#39;s price target\" data-tweet=\"$NVDA - Goldman Sachs ups Nvidia&#39;s price target https://seekingalpha.com/news/3300460-goldman-sachs-ups-nvidias-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3300460-goldman-sachs-ups-nvidias-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>49&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300459\" data-ts=\"1507738487\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACRX\" target=\"_blank\">ACRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300459-fda-action-date-tomorrow-for-acelrx-pharmas-pain-med-dsuvia-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA action date tomorrow for AcelRx Pharma&#39;s pain med Dsuvia; shares up 1%</a></h4><ul><li>The FDA's action date &#40;PDUFA&#41; for its review of AcelRx Pharmaceuticals' (<a href='https://seekingalpha.com/symbol/ACRX' title='AcelRx Pharmaceuticals, Inc.'>ACRX</a> <font color='green'>+0.9%</font>) marketing application seeking approval for pain med <a href=\"http://www.acelrx.com/pipeline/dsuvia.php\" target=\"_blank\">DSUVIA</a> (sufentanil sublingual tablet, 30 mcg) is tomorrow, October 12.</li><li>Shares have rallied&nbsp;<font color='green'>178%</font>&nbsp;since July in anticipation of good news.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3246654-fda-accepts-acelrxs-nda-pain-med-arxminus-04-action-date-october-12-shares-ahead-7-percent\" target=\"_blank\">FDA accepts AcelRx's NDA for pain med ARX-04; action date October 12; shares ahead 7% premarket</a> (Feb. 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3300459\" data-linked=\"FDA action date tomorrow for AcelRx Pharma&#39;s pain med Dsuvia; shares up 1%\" data-tweet=\"$ACRX - FDA action date tomorrow for AcelRx Pharma&#39;s pain med Dsuvia; shares up 1% https://seekingalpha.com/news/3300459-fda-action-date-tomorrow-for-acelrx-pharmas-pain-med-dsuvia-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3300459-fda-action-date-tomorrow-for-acelrx-pharmas-pain-med-dsuvia-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300454\" data-ts=\"1507737679\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300454-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/LBIX-OLD' title='Leading Brands Inc'>LBIX-OLD</a> <font color='green'>+89%</font>. <a href='https://seekingalpha.com/symbol/SYPR' title='Sypris Solutions, Inc.'>SYPR</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/OBCI' title='Ocean Bio-Chem, Inc.'>OBCI</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/NC' title='NACCO Industries Inc.'>NC</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/VOXX' title='VOXX International Corp.'>VOXX</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/KNDI' title='Kandi Technologies Group, Inc.'>KNDI</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/THST' title='Truett-Hurst, Inc.'>THST</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300454\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$LBIX-OLD $SYPR $OBCI - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3300454-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3300454-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300449\" data-ts=\"1507736669\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRY\" target=\"_blank\">CRY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300449-cryolife-takeout-of-higher-growing-jotec-fails-to-stem-selling-from-q3-revenue-miss-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CryoLife takeout of higher-growing JOTEC fails to stem selling from Q3 revenue miss; shares down 16%</a></h4><ul><li>Thinly traded small cap CryoLife (<a href='https://seekingalpha.com/symbol/CRY' title='CryoLife, Inc.'>CRY</a> <font color='red'>-15.7%</font>) slumps on more than double normal volume, albeit on turnover of only 321K shares, after it <a href=\"https://seekingalpha.com/pr/16964853-cryolife-announces-definitive-agreement-acquire-jotec\" target=\"_blank\">announced </a>Q3 revenues of $45.1M, shy of its previously announced guidance of $46.5M - 47.5M citing the negative impact of recent hurricanes in Florida and Texas.</li><li>Management will update its 2017 guidance during the Q3 earnings call.</li><li>After the close yesterday, the company announced its planned takeover of Germany-based <a href=\"https://www.jotec.com/en/\" target=\"_blank\">JOTEC GmbH</a>, a developer of surgical devices and endovascular implants, sporting a 17% CAGR in revenues of the past five years.</li><li>Under the terms of the agreement, CryoLife will pay $225M (75% cash/25% stock). It plans to finance the deal with cash on hand and borrowings under its new $255M credit facilities. The transaction should close this quarter.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300449\" data-linked=\"CryoLife takeout of higher-growing JOTEC fails to stem selling from Q3 revenue miss; shares down 16%\" data-tweet=\"$CRY - CryoLife takeout of higher-growing JOTEC fails to stem selling from Q3 revenue miss; shares down 16% https://seekingalpha.com/news/3300449-cryolife-takeout-of-higher-growing-jotec-fails-to-stem-selling-from-q3-revenue-miss-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3300449-cryolife-takeout-of-higher-growing-jotec-fails-to-stem-selling-from-q3-revenue-miss-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300450\" data-ts=\"1507736637\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FAST\" target=\"_blank\">FAST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300450-fastenal-falls-drags-down-peers-q3-margin-disappoints\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fastenal falls, drags down peers as Q3 margin disappoints</a></h4><ul>     <li>Fastenal (<a href='https://seekingalpha.com/symbol/FAST' title='Fastenal Company'>FAST</a> <font color='red'>-2%</font>) falls as much as 5% before stabilizing after <a href=\"https://seekingalpha.com/news/3300382-fastenal-minus-4-percent-q3-results-weighed-employee-costs-hurricanes\" target=\"_blank\">Q3 gross margin missed expectations</a> even as <a href=\"https://seekingalpha.com/news/3300327-fastenal-eps-line-beats-revenue\" target=\"_blank\">Q3 earnings</a> and revenues met estimates.</li>     <li>William Blair&rsquo;s Ryan Merkel says storm disruption and commodity inflation negatively affected FAST's Q3 gross margin, and customer and product mix remained negative as growth from vending, on-sites, national accounts and non-fasteners continue to outpace smaller accounts and fasteners where margins are higher.</li>     <li>Merkel, who rates FAST at Outperform, still thinks an improving industrial economy can deliver double-digit EPS growth despite the negative mix.</li>     <li>Morgan Stanley&rsquo;s Jiayan Zhou calls a results a \"mixed bag\" and is encouraged by September's strong daily sales performance but wonders about any tailwind from recovery demand related to the hurricanes, as distributors from the firm&rsquo;s Q3 survey broadly pointed to the storms as a modest top line benefit.</li>     <li>Peers MSC Industrial (<a href='https://seekingalpha.com/symbol/MSM' title='MSC Industrial Direct Co. Inc.'>MSM</a> <font color='red'>-1.9%</font>), Grainger (<a href='https://seekingalpha.com/symbol/GWW' title='W.W. Grainger, Inc.'>GWW</a> <font color='red'>-1.7%</font>), Wesco (<a href='https://seekingalpha.com/symbol/WCC' title='WESCO International, Inc.'>WCC</a> <font color='red'>-0.4%</font>) and HD Supply (<a href='https://seekingalpha.com/symbol/HDS' title='HD Supply'>HDS</a> <font color='red'>-2%</font>) also are lower.</li>     <li>Source:&nbsp;Briefing.com</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300450\" data-linked=\"Fastenal falls, drags down peers as Q3 margin disappoints\" data-tweet=\"$FAST $FAST $MSM - Fastenal falls, drags down peers as Q3 margin disappoints https://seekingalpha.com/news/3300450-fastenal-falls-drags-down-peers-q3-margin-disappoints?source=tweet\" data-url=\"https://seekingalpha.com/news/3300450-fastenal-falls-drags-down-peers-q3-margin-disappoints\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300446\" data-ts=\"1507735496\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HIMX\" target=\"_blank\">HIMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300446-mizuho-downgrades-himax\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mizuho downgrades Himax</a></h4><ul><li>        Mizuho Securities <a href=\"https://www.streetinsider.com/Special+Reports/Pre-Open+Stock+Movers+1011%3A+%28IDXG%29+%28HMNY%29+%28ATHX%29+Higher%3B+%28HDSN%29+%28CUDA%29+%28MNKD%29+Lower+%28more...%29/13379848.html\" target=\"_blank\">downgrades</a> Himax Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/HIMX' title='Himax Technologies, Inc.'>HIMX</a>) from Outperform to Neutral.</li><li>                  Latest analyst standings for Himax: 2 Buy, 7 Outperform, 1 Underperform, and 1 Sell.    </li><li>               Median price target: $11.50.&nbsp;</li><li>Himax shares are&nbsp;<font color='red'>down 6.56%</font>.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3300446\" data-linked=\"Mizuho downgrades Himax\" data-tweet=\"$HIMX - Mizuho downgrades Himax https://seekingalpha.com/news/3300446-mizuho-downgrades-himax?source=tweet\" data-url=\"https://seekingalpha.com/news/3300446-mizuho-downgrades-himax\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>109&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300442\" data-ts=\"1507735104\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AERI\" target=\"_blank\">AERI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300442-aerie-pharma-breaks-out-ahead-of-ad-com-review-of-rhopressa-for-lowering-iop-shares-up-19\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aerie Pharma breaks out ahead of Ad Com review of Rhopressa for lowering IOP; shares up 19%</a></h4><ul><li>Aerie Pharmaceuticals (<a href='https://seekingalpha.com/symbol/AERI' title='Aerie Pharmaceuticals, Inc.'>AERI</a> <font color='green'>+18.5%</font>) jumps on more than double normal volume ahead of Thursday's FDA <a href=\"https://www.fda.gov/AdvisoryCommittees/Calendar/ucm576950.htm\" target=\"_blank\">Ad Com review</a> of its marketing application seeking approval for Rhopressa (netarsudil ophthalmic solution) 0.02% to reduce elevated intraocular pressure &#40;IOP&#41; in patients with open-angle glaucoma or ocular hypertension.</li><li>According comments in the briefing materials (p34 in FDA doc), the review team agrees that Rhopressa is efficacious for the indication.</li><li><a href=\"https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DermatologicandOphthalmicDrugsAdvisoryCommittee/UCM579730.pdf\" target=\"_blank\">FDA briefing doc&nbsp;</a></li><li><a href=\"https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DermatologicandOphthalmicDrugsAdvisoryCommittee/UCM579731.pdf\" target=\"_blank\">Company briefing doc</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3300442\" data-linked=\"Aerie Pharma breaks out ahead of Ad Com review of Rhopressa for lowering IOP; shares up 19%\" data-tweet=\"$AERI - Aerie Pharma breaks out ahead of Ad Com review of Rhopressa for lowering IOP; shares up 19% https://seekingalpha.com/news/3300442-aerie-pharma-breaks-out-ahead-of-ad-com-review-of-rhopressa-for-lowering-iop-shares-up-19?source=tweet\" data-url=\"https://seekingalpha.com/news/3300442-aerie-pharma-breaks-out-ahead-of-ad-com-review-of-rhopressa-for-lowering-iop-shares-up-19\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300443\" data-ts=\"1507735098\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKAM\" target=\"_blank\">AKAM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300443-akamai-acquires-nominum\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Akamai acquires Nominum</a></h4><ul><li>        Akamai (NASDAQ:<a href='https://seekingalpha.com/symbol/AKAM' title='Akamai Technologies, Inc.'>AKAM</a>) <a href=\"https://seekingalpha.com/pr/16965171-akamai-agrees-acquire-nominum\" target=\"_blank\">acquires</a> DNS and enterprise security solution company Nominum for an undisclosed amount.</li><li>                  The all-cash transaction will close this quarter.    </li><li>               Akamai expects the acquisition to dilute non-GAAP earnings by $0.05 in Q4 and by $0.11 in FY18 before becoming accretive in FY19. &nbsp;&nbsp;</li><li>Akamai shares are&nbsp;<font color='red'>down 2.02%.</font>&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3300443\" data-linked=\"Akamai acquires Nominum\" data-tweet=\"$AKAM - Akamai acquires Nominum https://seekingalpha.com/news/3300443-akamai-acquires-nominum?source=tweet\" data-url=\"https://seekingalpha.com/news/3300443-akamai-acquires-nominum\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300441\" data-ts=\"1507734634\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IBM\" target=\"_blank\">IBM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300441-ibm-majesco-announce-cloud-based-insurance-platform\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IBM, Majesco announce cloud-based insurance platform</a></h4><ul><li>        IBM (NYSE:<a href='https://seekingalpha.com/symbol/IBM' title='International Business Machines Corporation'>IBM</a>) <a href=\"http://www-03.ibm.com/press/us/en/pressrelease/53284.wss\" target=\"_blank\">announces</a> a new cloud-based insurance platform in conjunction with MetLife (NYSE:<a href='https://seekingalpha.com/symbol/MET' title='MetLife, Inc.'>MET</a>) and Majesco (NYSEMKT:<a href='https://seekingalpha.com/symbol/MJCO' title='Majesco'>MJCO</a>).</li><li>               The IBM Insurance Platform will combine cognitive computing, data analytics, and security features to help insurers expand products and attract customers. The Platform builds on the IBM Cloud.&nbsp;</li><li>               Insurance software company Majesco contributed underwriting, policy administration, billings, and claims functions to the Platform.&nbsp;</li><li>               Majesco shares are&nbsp;<font color='green'>up 7.98%</font>. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3300441\" data-linked=\"IBM, Majesco announce cloud-based insurance platform\" data-tweet=\"$IBM $IBM $MET - IBM, Majesco announce cloud-based insurance platform https://seekingalpha.com/news/3300441-ibm-majesco-announce-cloud-based-insurance-platform?source=tweet\" data-url=\"https://seekingalpha.com/news/3300441-ibm-majesco-announce-cloud-based-insurance-platform\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300440\" data-ts=\"1507734454\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHS\" target=\"_blank\">CHS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300440-chicos-fas-hit-baml-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chico&#39;s FAS hit by BAML downgrade</a></h4><ul><li>Shares of Chico's FAS (<a href='https://seekingalpha.com/symbol/CHS' title='Chico&#39;s FAS, Inc.'>CHS</a> <font color='red'>-8.9%</font>) fall after a biting <a href=\"https://twitter.com/RatingsNetwork/status/918074810831339520\" target=\"_blank\">downgrade</a> from Bank of America Merrill Lynch.</li><li>BAML's note hits the common retail theme of intense promotional activity and weak mall trends.</li><li>Sales declines are forecast on Chico's for FY18 and FY19.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300440\" data-linked=\"Chico&#39;s FAS hit by BAML downgrade\" data-tweet=\"$CHS - Chico&#39;s FAS hit by BAML downgrade https://seekingalpha.com/news/3300440-chicos-fas-hit-baml-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3300440-chicos-fas-hit-baml-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300439\" data-ts=\"1507734173\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DCTH\" target=\"_blank\">DCTH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300439-delcath-files-sminus-1-for-equity-offering-shares-down-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Delcath files S-1 for equity offering; shares down 5%</a></h4><ul><li>Delcath Systems (<a href='https://seekingalpha.com/symbol/DCTH' title='Delcath Systems, Inc.'>OTC:DCTH</a> <font color='red'>-5.3%</font>) filed an <a href=\"https://www.sec.gov/Archives/edgar/data/872912/000119312517307479/d296322ds1.htm\" target=\"_blank\">S-1 </a>yesterday after the close for a proposed $64.5M equity offering of Units, each consisting of one share of common stock and one&nbsp; warrant to purchase one share of common.</li><li>Pricing and terms have yet to be determined.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300439\" data-linked=\"Delcath files S-1 for equity offering; shares down 5%\" data-tweet=\"$DCTH - Delcath files S-1 for equity offering; shares down 5% https://seekingalpha.com/news/3300439-delcath-files-sminus-1-for-equity-offering-shares-down-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3300439-delcath-files-sminus-1-for-equity-offering-shares-down-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300410\" data-ts=\"1507734034\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300410-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CASI' title='CASI Pharmaceuticals'>CASI</a> <font color='green'>+69%</font>. BIOP <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/AERI' title='Aerie Pharmaceuticals, Inc.'>AERI</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/SRNE' title='Sorrento Therapeutics, Inc.'>SRNE</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/MACK' title='Merrimack Pharmaceuticals'>MACK</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CRY' title='CryoLife, Inc.'>CRY</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/CHMA' title='Chiasma'>CHMA</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/IPCI' title='IntelliPharmaCeutics International Inc'>IPCI</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations'>HIIQ</a> <font color='red'>-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300410\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$CASI $RIOT $AERI - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3300410-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3300410-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300437\" data-ts=\"1507733590\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WPP\" target=\"_blank\">WPP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300437-ad-agencies-dip-credit-suisse-trims-estimates-on-media-buying\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ad agencies dip as Credit Suisse trims estimates on media buying</a></h4><ul>   <li>Ad agencies are trending lower today as Credit Suisse trims price targets while staying generally positive on prospects and valuation.</li>    <li>Interpublic Group (<a href=\"http://seekingalpha.com/symbol/IPG\" target=\"_blank\">IPG</a> <font color='red'>-1.5%</font>) is seeing its target clipped to $26 from a previous $27 as the firm sees lower organic revenue growth and a risk in U.S. media buying (about 6% of IPG's EBIT) where clients divert fees to targeted linear TV campaigns.</li>    <li>CS has cut its EPS forecasts for IPG to $1.59 in 2018 and $1.74 in 2019. But it's sticking with an Outperform rating, as IPG's risk compared to peers is minimal and the valuation is still attractive.</li>    <li>It's also decreased target price for Omnicom (<a href=\"http://seekingalpha.com/symbol/OMC\" target=\"_blank\">OMC</a> <font color='red'>-0.4%</font>) to $78 from $79, and its 2018/2019 EPS by 1% (to $5.38/$5.81) on similar risk, but rates the stock Neutral. It expects 2% organic revenue growth in Q3, vs. Q2's 3.5% and Q1's 4.4%. \"We believe OMC's advertising business will continue to slow, despite easier comps, as client spending from key verticals including FMCG remains muted.\"</li>    <li>Peer WPP (WPPGY) is <font color='red'>down 2.4%</font> and hanging just fractionally above a 52-week low of $89.40.</li>    <li>Credit Suisse's target on IPG still sees 25.7% upside, while its Omnicom target implies 5% upside.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300437\" data-linked=\"Ad agencies dip as Credit Suisse trims estimates on media buying\" data-tweet=\"$WPP $WPP $IPG - Ad agencies dip as Credit Suisse trims estimates on media buying https://seekingalpha.com/news/3300437-ad-agencies-dip-credit-suisse-trims-estimates-on-media-buying?source=tweet\" data-url=\"https://seekingalpha.com/news/3300437-ad-agencies-dip-credit-suisse-trims-estimates-on-media-buying\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300436\" data-ts=\"1507733585\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DKS\" target=\"_blank\">DKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300436-dicks-to-52-week-low-after-wells-warns-on-margins\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dick&#39;s to 52-week low after Wells warns on margins</a></h4><ul><li>Dick's Sporting Goods (<a href='https://seekingalpha.com/symbol/DKS' title='Dick&#39;s Sporting Goods, Inc.'>DKS</a> <font color='red'>-4.8%</font>) falls after Wells Fargo <a href=\"https://www.streetinsider.com/Analyst+Comments/Wells+Fargo+Resumes+Dicks+Sporting+Goods+%28DKS%29+at+Market+Perform/13378702.html\" target=\"_blank\">warns</a> that margins could be sacrificed by the sports retailer for an extended period as it looks to protect market share.</li><li>An analogy is drawn by analyst Tom Nikic with Best Buy, which saw four years of margin erosion in its turnaround cycle.</li><li>Shares of Dick's hit a 52-week low of $25.22 earlier.</li><li>Sources: StreetInsider and Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3300436\" data-linked=\"Dick&#39;s to 52-week low after Wells warns on margins\" data-tweet=\"$DKS - Dick&#39;s to 52-week low after Wells warns on margins https://seekingalpha.com/news/3300436-dicks-to-52-week-low-after-wells-warns-on-margins?source=tweet\" data-url=\"https://seekingalpha.com/news/3300436-dicks-to-52-week-low-after-wells-warns-on-margins\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300433\" data-ts=\"1507733037\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HMNY\" target=\"_blank\">HMNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300433-rally-continues-for-helios-matheson-analytics\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rally continues for Helios &amp; Matheson Analytics</a></h4><ul><li>Helios and Matheson Analytics (<a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+28.8%</font>) skyrockets again as investors jump on the idea that MoviePass will redefine the movie theater business.</li><li>Shares of H&amp;M&nbsp;traded as high as $38.86 earlier.</li><li>Not everyone is smitten. Citron Research <a href=\"https://twitter.com/CitronResearch/status/918109339897835520\" target=\"_blank\">tweets</a> that \"retail investors are warned\" about what the firm sees as a money-losing operation.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3300142-helios-and-matheson-plus-700-percent-month-called\" target=\"_blank\">Helios &amp; Matheson up +700% in a month, here's who called it</a> (Oct. 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3300433\" data-linked=\"Rally continues for Helios &amp; Matheson Analytics\" data-tweet=\"$HMNY - Rally continues for Helios &amp; Matheson Analytics https://seekingalpha.com/news/3300433-rally-continues-for-helios-matheson-analytics?source=tweet\" data-url=\"https://seekingalpha.com/news/3300433-rally-continues-for-helios-matheson-analytics\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>59&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300430\" data-ts=\"1507732590\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BOJA\" target=\"_blank\">BOJA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300430-bojangles-slides-after-stephens-turns-cautious\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bojangles slides after Stephens turns cautious</a></h4><ul><li>Bojangles (<a href='https://seekingalpha.com/symbol/BOJA' title='Bojangles&#39;'>BOJA</a> <font color='red'>-4.8%</font>) falls sharply after Stephens downgrades the restaurant stock to Equal-weight from Overweight and sets a new price target of $14.</li><li>The firm thinks Bojangles is at risk of losing market share to larger QSR chains with larger marketing budgets.</li><li>Shares hit a 52-week low of $12.40 earlier today.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300430\" data-linked=\"Bojangles slides after Stephens turns cautious\" data-tweet=\"$BOJA - Bojangles slides after Stephens turns cautious https://seekingalpha.com/news/3300430-bojangles-slides-after-stephens-turns-cautious?source=tweet\" data-url=\"https://seekingalpha.com/news/3300430-bojangles-slides-after-stephens-turns-cautious\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300424\" data-ts=\"1507731883\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300424-ge-to-cnbc-maintaining-dividend-top-priority\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GE to CNBC: Maintaining dividend a top priority</a></h4><ul>     <li>\"<a href=\"https://finance.yahoo.com/video/ge-says-dividend-remains-top-131600458.html\" target=\"_blank\">The dividend remains a top priority</a>,\" General Electric (<a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a> <font color='red'>-1.1%</font>) says in a statement to CNBC in response to comments by J.P. Morgan analyst Stephen Tusa that a GE dividend cut is <a href=\"https://seekingalpha.com/news/3300354-ge-dividend-cut-increasingly-likely-jpm-cuts-stock-price-target-20\" target=\"_blank\">increasingly likely</a>.</li><li>William Blair analyst Nick Heymann agrees with GE, saying a dividend cut is \"<a href=\"https://www.cnbc.com/video/2017/10/11/the-last-thing-ge-will-do-is-cut-its-dividend-william-blair-analyst.html\" target=\"_blank\">the last thing</a>\" the company would do.</li><li>\"They're going to cut capital spending, they're going to cut costs radically... a dividend cut would shake a lot of people's confidence,\" Heymann tells CNBC.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300424\" data-linked=\"GE to CNBC: Maintaining dividend a top priority\" data-tweet=\"$GE - GE to CNBC: Maintaining dividend a top priority https://seekingalpha.com/news/3300424-ge-to-cnbc-maintaining-dividend-top-priority?source=tweet\" data-url=\"https://seekingalpha.com/news/3300424-ge-to-cnbc-maintaining-dividend-top-priority\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>37&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300420\" data-ts=\"1507731365\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMG\" target=\"_blank\">CMG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300420-wedbush-cuts-estimates-on-chipotle\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wedbush cuts estimates on Chipotle</a></h4><ul> <li>Chipotle (<a href='https://seekingalpha.com/symbol/CMG' title='Chipotle Mexican Grill, Inc.'>CMG</a> <font color='red'>-0.9%</font>) falls back after Wedbush lowers estimates to below the consensus mark of Wall Street analysts.</li> <li>Analyst Nick Setyan now sees Q3 comparable sales of -0.2% vs. +3.8% prior view and a Q4 comp mark of +2.8%. The softer outlook on sales leads to a downward revision on full-year EPS to $7.24 vs. $8.55 prior and $7.55 consensus.</li> <li>Sources: Bloomberg and Yahoo Finance</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300420\" data-linked=\"Wedbush cuts estimates on Chipotle\" data-tweet=\"$CMG - Wedbush cuts estimates on Chipotle https://seekingalpha.com/news/3300420-wedbush-cuts-estimates-on-chipotle?source=tweet\" data-url=\"https://seekingalpha.com/news/3300420-wedbush-cuts-estimates-on-chipotle\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300416\" data-ts=\"1507730644\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGEN\" target=\"_blank\">SGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300416-seattle-genetics-launches-two-clinical-trial-collaborations-for-cancer-therapy-candidate-sgn\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seattle Genetics launches two clinical trial collaborations for cancer therapy candidate SGN-LIV1A; shares ahead 2%</a></h4><ul><li>Seattle Genetics (<a href='https://seekingalpha.com/symbol/SGEN' title='Seattle Genetics, Inc.'>SGEN</a> <font color='green'>+1.6%</font>) <a href=\"https://seekingalpha.com/pr/16965209-seattle-genetics-announces-additional-clinical-collaborations-evaluate-sgn-liv1a-triple\" target=\"_blank\">announces </a>two clinical trial collaborations supporting antibody-drug conjugate &#40;ADC&#41; SGN-LIV1A in patients with triple negative breast cancer &#40;TNBC&#41;.</li><li>The first is a Phase 1b/2 study assessing the combination of SGN-LIV1A and Merck's KEYTRUDA (pembrolizumab) in a first-line setting.</li><li>The second will evaluate SGN-LIV1A with standard chemo (doxorubicin and cyclophosphamide) as neoadjuvant treatment in a Phase 2 in newly diagnosed patients with Stage 2 or 3 HER2-negative breast cancer.</li><li>SGN-LIV1A targets the LIV-1 protein, expressed by most metastatic breast cancers.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300416\" data-linked=\"Seattle Genetics launches two clinical trial collaborations for cancer therapy candidate SGN-LIV1A; shares ahead 2%\" data-tweet=\"$SGEN - Seattle Genetics launches two clinical trial collaborations for cancer therapy candidate SGN-LIV1A; shares ahead 2% https://seekingalpha.com/news/3300416-seattle-genetics-launches-two-clinical-trial-collaborations-for-cancer-therapy-candidate-sgn?source=tweet\" data-url=\"https://seekingalpha.com/news/3300416-seattle-genetics-launches-two-clinical-trial-collaborations-for-cancer-therapy-candidate-sgn\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300406\" data-ts=\"1507729089\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KR\" target=\"_blank\">KR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300406-kroger-rallies-after-strategy-reset-announced\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kroger rallies after strategy reset announced</a></h4><ul>     <li>Kroger (NYSE:<a href='https://seekingalpha.com/symbol/KR' title='Kroger Co.'>KR</a>) announces a strategy reset in front of its presentation at its investor day event.</li>     <li>The company says its \"Restock Kroger Plan\" will be fueled by capital investments, cost savings and free cash flow.</li>     <li>Kroger plans to expand partnerships to create customer value, including utilizing more of its capital to fund technology/infrastructure upgrades and create alternative revenue streams.</li>     <li>Kroger will continue building its Internet of Things sensor network, video analytics and machine learning networks and complement those innovations with robotics and artificial intelligence to transform the customer experience.</li>     <li>The Restock Kroger plan is expected to generate $400M in incremental operating margin by 2020. Also, the company expects to generate more than $4B&nbsp;of free cash flow over the next three years &ndash; nearly double what was generated over the previous three years.</li>         <li>Kroger also tipped its plan to explore strategic alternatives for its convenience store business, including a potential sale. The company hired Goldman Sachs to identify, review and evaluate the options.</li>     <li>Looking at financial numbers, Kroger&nbsp;expects identical supermarket sales to improve in 2018 and for EPS to be flat to slightly up.</li>  <li>\"We have the scale, the data, physical assets and human connection to win,\" promises CEO Rodney McMullen.</li>     <li>KR  <font color='green'>+4.38%</font> premarket to  $21.43.</li>     <li>Source: <a href=\"https://seekingalpha.com/pr/16965616-kroger-outlines-plan-redefine-way-america-eats-deliver-value-customers-and-shareholders\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3300406\" data-linked=\"Kroger rallies after strategy reset announced\" data-tweet=\"$KR - Kroger rallies after strategy reset announced https://seekingalpha.com/news/3300406-kroger-rallies-after-strategy-reset-announced?source=tweet\" data-url=\"https://seekingalpha.com/news/3300406-kroger-rallies-after-strategy-reset-announced\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>45&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300405\" data-ts=\"1507728799\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LODE\" target=\"_blank\">LODE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300405-comstock-mining-cuts-long-term-debt-nearly-1m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Comstock Mining cuts long-term debt by nearly $1M</a></h4><ul>     <li>Comstock Mining (<a href='https://seekingalpha.com/symbol/LODE' title='Comstock Mining Inc'>LODE</a>) says it has <a href=\"https://seekingalpha.com/pr/16965095-comstock-mining-reduces-long-term-debt-almost-1-million\" target=\"_blank\">reduced long-term debt by nearly $1M</a> to $9.9M.</li>     <li>LODE says it has received proceeds from  the sale of 53 acre-feet of water rights, and the sale of other smaller non-mining properties in Gold Hill and Silver City, Nev., and its recently announced <a href=\"https://seekingalpha.com/pr/16960877-tonogold-announces-strategic-gold-joint-venture\" target=\"_blank\">joint venture</a> with Tonogold Resources.</li>     <li>LODE says it still plans to sell ~$14M in non-mining assets targeted to eliminate the remainder of its debt.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300405\" data-linked=\"Comstock Mining cuts long-term debt by nearly $1M\" data-tweet=\"$LODE - Comstock Mining cuts long-term debt by nearly $1M https://seekingalpha.com/news/3300405-comstock-mining-cuts-long-term-debt-nearly-1m?source=tweet\" data-url=\"https://seekingalpha.com/news/3300405-comstock-mining-cuts-long-term-debt-nearly-1m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300403\" data-ts=\"1507728536\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANGI\" target=\"_blank\">ANGI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300403-angiplus-3_5-goldman-assumes-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ANGI +3.5% as Goldman assumes at Buy</a></h4><ul>   <li>ANGI Homeservices (NASDAQ:<a href='https://seekingalpha.com/symbol/ANGI' title='ANGI Homeservices Inc.'>ANGI</a>) is <font color='green'>up 3.5%</font> premarket after being assumed Buy at Goldman Sachs.</li>    <li>Most recent ratings are of the Buy variety for the new ANGI, created as part of the buyout by IAC/InterActiveCorp. CIBC started coverage at Outperform last week, and on the same day Oppenheimer reiterated its Outperform rating; each has a $14 price target, implying 21% upside.</li>    <li>Shares are <font color='green'>up 47.7%</font> YTD.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300403\" data-linked=\"ANGI +3.5% as Goldman assumes at Buy\" data-tweet=\"$ANGI - ANGI +3.5% as Goldman assumes at Buy https://seekingalpha.com/news/3300403-angiplus-3_5-goldman-assumes-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3300403-angiplus-3_5-goldman-assumes-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300398\" data-ts=\"1507728050\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300398-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/RGSE' title='RGS Energy, Inc.'>RGSE</a>&nbsp;<font color='green'>+41%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a>&nbsp;<font color='green'>+19%</font>&nbsp;on 40%&nbsp;<a href=\"https://seekingalpha.com/news/3300388-interpace-25-percent-premarket-40-percent-reimbursement-boost-thygenx\" target=\"_blank\">reimbursement</a>&nbsp;boost for ThyGenX.</li>     <li><a href='https://seekingalpha.com/symbol/CASI' title='CASI Pharmaceuticals'>CASI</a>&nbsp;<font color='green'>+19%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a>&nbsp;<font color='green'>+19%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/ATHX' title='Athersys, Inc.'>ATHX</a>&nbsp;<font color='green'>+14%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/pr/16965068-athersys-nikon-cell-innovation-collaborate-multistem-commercial-manufacturing-japan\" target=\"_blank\">entering</a>&nbsp;into a manufacturing services agreement with&nbsp;Nikon CeLL&nbsp;innovation.&nbsp;</li>     <li><a href='https://seekingalpha.com/symbol/ANY' title='Sphere 3D Corp.'>ANY</a>&nbsp;<font color='green'>+13%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/pr/16965386-sphere-3d-announces-favorable-ruling-dismissal-lawsuit\" target=\"_blank\">dismissal</a>&nbsp;of lawsuit and favorable ruling.</li>     <li>WPCS&nbsp;<font color='green'>+9%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/AERI' title='Aerie Pharmaceuticals, Inc.'>AERI</a>&nbsp;<font color='green'>+12%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/MLSS' title='Milestone Scientific Inc.'>MLSS</a>&nbsp;<font color='green'>+11%</font>&nbsp;as CompuFlo Epidural System has been&nbsp;<a href=\"https://seekingalpha.com/pr/16965157-milestone-scientific-announces-500-successful-procedures-using-compuflo-r-epidural-system\" target=\"_blank\">successfully</a>&nbsp;utilized in over 500 epidural procedures.</li>     <li><a href='https://seekingalpha.com/symbol/CLSN' title='Celsion Corporation'>CLSN</a>&nbsp;<font color='green'>+9%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a>&nbsp;<font color='green'>+7%</font>&nbsp;on strategic&nbsp;<a href=\"https://seekingalpha.com/news/3300373-moleculin-strategically-collaborates-develop-immune-stimulation-drug-shares-ahead-6-percent\" target=\"_blank\">collaboration</a>&nbsp;to develop immune stimulation drug.</li>     <li><a href='https://seekingalpha.com/symbol/CLRB' title='Cellectar Biosciences, Inc.'>CLRB</a>&nbsp;<font color='green'>+7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300398\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$RGSE $IDXG $CASI - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3300398-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3300398-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300397\" data-ts=\"1507727979\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300397-snapplus-2_5-credit-suisse-raises-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Snap +2.5% as Credit Suisse raises price target</a></h4><ul>   <li>Snap (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>) is <font color='green'>up 2.5%</font> premarket after getting a higher price target from Credit Suisse, which is bumping user estimates and expects <a href=\"https://www.streetinsider.com/Analyst+Comments/Snap+Inc+%28SNAP%29+PT+Raised+to+%2420+at+Credit+Suisse%3B+CPMs+Likely+Stabilizing/13379295.html\" target=\"_blank\">CPMs are stabilizing and even increasing</a> slightly.</li>    <li>The firm raised its target to $20 from $17, implying 39.5% upside from yesterday's close, and analyst Stephen Ju increased his estimates for North American daily active users -- to about 3.2M sequential adds, from a previous 1.5M.</li>    <li>Longer term, the firm has an Outperform rating resting on three factors: \"(1) we believe SNAP shares at current levels are now exhibiting asymmetric risk/reward to the upside, with downside risk of ~6% in our Grey Sky scenario and upside potential of ~39% to our target, (2) it is a scarce asset that offers advertisers access to a coveted younger demographic; and (3) Snap is a margin expansion story with revenue CAGR exceeding cost of sales CAGR.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300397\" data-linked=\"Snap +2.5% as Credit Suisse raises price target\" data-tweet=\"$SNAP - Snap +2.5% as Credit Suisse raises price target https://seekingalpha.com/news/3300397-snapplus-2_5-credit-suisse-raises-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3300397-snapplus-2_5-credit-suisse-raises-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>110&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300393\" data-ts=\"1507727473\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300393-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/HDSN' title='Hudson Technologies, Inc.'>HDSN</a>&nbsp;<font color='red'>-17%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3300306-hudson-technologies-minus-9_5-percent-issuing-consensus-q3-guidance\" target=\"_blank\">issuing</a> below consensus Q3 guidance.</li><li><a href='https://seekingalpha.com/symbol/IPCI' title='IntelliPharmaCeutics International Inc'>IPCI</a>&nbsp;<font color='red'>-13%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3300384-intellipharmaceutics-inks-4m-capital-raise-shares-16-percent-premarket\" target=\"_blank\">announcing</a> $4M registered direct offering.</li><li><a href='https://seekingalpha.com/symbol/CUDA' title='Barracuda Networks, Inc'>CUDA</a>&nbsp;<font color='red'>-9%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3300256-barracuda-networks-eps-line-beats-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a>&nbsp;<font color='red'>-7%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3300360-mannkind-sees-q3-net-afrezza-sales-2m-shares-7-percent-premarket-equity-offering\" target=\"_blank\">announcing</a> $61M direct offering of common stock.</li><li><a href='https://seekingalpha.com/symbol/ROKA' title='Roka Bioscience'>ROKA</a> <font color='red'>-5%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3300393\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$HDSN $IPCI $CUDA - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3300393-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3300393-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300390\" data-ts=\"1507727199\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JBLU\" target=\"_blank\">JBLU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300390-jetblue-updates-on-hurricane-impact\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JetBlue updates on hurricane impact</a></h4><ul> <li>JetBlue (NASDAQ:<a href='https://seekingalpha.com/symbol/JBLU' title='JetBlue Airways Corporation'>JBLU</a>) <a href=\"https://seekingalpha.com/pr/16965212-jetblue-airways-reports-september-traffic\" target=\"_blank\">reports</a> traffic fell 4.4% to 3.28B revenue passenger miles during the hurricane-impacted month of September.</li> <li>Capacity was down 0.9% to 4.089B available seat miles.</li> <li>The carrier's load factor fell 300 bps to 80.2%.</li> <li>JetBlue says the hurricanes lopped off $44M from revenue and about $30M to $35M from operating income.</li><li>Looking at the impact of the hurricanes on all of Q4, JetBlue sees revenue per available seat mile falling 1% to 2% due to Irma and Maria, while its cost per available seat mile will be up about 2.5%. Adding it all up JetBlue, expects revenue to be negatively impacted by $70M to $90M.</li> <li>JBLU <font color='red'>-1.88%</font> premarket to $19.85.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3300390\" data-linked=\"JetBlue updates on hurricane impact\" data-tweet=\"$JBLU - JetBlue updates on hurricane impact https://seekingalpha.com/news/3300390-jetblue-updates-on-hurricane-impact?source=tweet\" data-url=\"https://seekingalpha.com/news/3300390-jetblue-updates-on-hurricane-impact\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300388\" data-ts=\"1507726866\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDXG\" target=\"_blank\">IDXG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300388-interpace-up-25-premarket-on-40-reimbursement-boost-for-thygenx\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Interpace up 25% premarket on 40% reimbursement boost for ThyGenX</a></h4><ul><li>Interpace Diagnostics (NASDAQ:<a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a>) jumps&nbsp;<font color='green'>25%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16965429-interpace-diagnostics-announces-increased-reimbursement-thygenx\" target=\"_blank\">announcement </a>that Medicare reimbursement for its ThyGenX molecular test will increase 40% effective January 1, 2018.</li><li>Medicare represents ~40% of ThyGenX volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300388\" data-linked=\"Interpace up 25% premarket on 40% reimbursement boost for ThyGenX\" data-tweet=\"$IDXG - Interpace up 25% premarket on 40% reimbursement boost for ThyGenX https://seekingalpha.com/news/3300388-interpace-up-25-premarket-on-40-reimbursement-boost-for-thygenx?source=tweet\" data-url=\"https://seekingalpha.com/news/3300388-interpace-up-25-premarket-on-40-reimbursement-boost-for-thygenx\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300384\" data-ts=\"1507726454\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IPCI\" target=\"_blank\">IPCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300384-intellipharmaceutics-inks-4m-capital-raise-shares-down-16-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intellipharmaceutics inks $4M capital raise; shares down 16% premarket</a></h4><ul><li>Thinly traded nano cap Intellipharmaceutics (NASDAQ:<a href='https://seekingalpha.com/symbol/IPCI' title='IntelliPharmaCeutics International Inc'>IPCI</a>) slumps&nbsp;<font color='red'>16%</font>&nbsp;premarket on modestly higher volume in response to its <a href=\"https://seekingalpha.com/pr/16965310-intellipharmaceutics-announces-us-4-million-registered-direct-offering\" target=\"_blank\">direct placement</a> of 3,636,364 shares of common stock at $1.10 per share and unregistered 30-month warrants to purchase up to 1,818,182 shares at $1.25 to institutional investors. Closing date is October 13.</li><li>Yesterday's close was $1.15.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300384\" data-linked=\"Intellipharmaceutics inks $4M capital raise; shares down 16% premarket\" data-tweet=\"$IPCI - Intellipharmaceutics inks $4M capital raise; shares down 16% premarket https://seekingalpha.com/news/3300384-intellipharmaceutics-inks-4m-capital-raise-shares-down-16-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3300384-intellipharmaceutics-inks-4m-capital-raise-shares-down-16-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300382\" data-ts=\"1507726372\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FAST\" target=\"_blank\">FAST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300382-fastenalminus-4-q3-results-weighed-employee-costs-hurricanes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fastenal -4% as Q3 results weighed by employee costs, hurricanes</a></h4><ul>     <li>Fastenal (NASDAQ:<a href='https://seekingalpha.com/symbol/FAST' title='Fastenal Company'>FAST</a>) <font color='red'>-4.1%</font> premarket after reporting in-line <a href=\"https://seekingalpha.com/news/3300327-fastenal-eps-line-beats-revenue\" target=\"_blank\">Q3 earnings</a> and revenue, but results were <a href=\"http://www.marketwatch.com/story/fastenal-shares-slide-19-premarket-after-earnings-2017-10-11\" target=\"_blank\">held down</a> by higher employee costs and the impact of hurricanes.</li>     <li>FAST says employee-related costs rose 12.3% in the quarter, due to higher bonuses and commissions from growth in sales and earnings, an increase in headcount, higher health care costs and the inclusion of workers from its Mansco acquisition.</li>     <li>FAST also says Q3 sales and gross profit was hurt by the effects of hurricanes during the quarter, which resulted in an increase in sales of lower margin products; Q3 gross profit fell to 49.1% from 49.3% in the year-ago quarter.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300382\" data-linked=\"Fastenal -4% as Q3 results weighed by employee costs, hurricanes\" data-tweet=\"$FAST - Fastenal -4% as Q3 results weighed by employee costs, hurricanes https://seekingalpha.com/news/3300382-fastenalminus-4-q3-results-weighed-employee-costs-hurricanes?source=tweet\" data-url=\"https://seekingalpha.com/news/3300382-fastenalminus-4-q3-results-weighed-employee-costs-hurricanes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300376\" data-ts=\"1507725220\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLNO\" target=\"_blank\">SLNO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300376-soleno-nabs-u-s-patent-covering-lead-candidate-diazoxide-shares-ahead-5-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Soleno nabs U.S. patent covering lead candidate diazoxide; shares ahead 5% premarket</a></h4><ul><li>Thinly traded nano cap Soleno Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SLNO' title='Soleno Therapeutics, Inc.'>SLNO</a>) is up&nbsp;<font color='green'>5%</font>&nbsp;premarket on light volume in response its <a href=\"https://seekingalpha.com/pr/16965283-soleno-therapeutics-announces-issuance-new-u-s-patent-dccr-covering-treatment-hyperphagia\" target=\"_blank\">announcement </a>that the USPTO has issued it an new patent (No. 9,782,416) covering the use of <a href=\"http://soleno.life/dccr/\" target=\"_blank\">diazoxide </a>to treat hyperphagia (excessive hunger) in patients with Prader-Willi syndrome &#40;PWS&#41;.</li><li>The company expects to launch a Phase 3 clinical trial assessing diazoxide in PWS by year-end.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300376\" data-linked=\"Soleno nabs U.S. patent covering lead candidate diazoxide; shares ahead 5% premarket\" data-tweet=\"$SLNO - Soleno nabs U.S. patent covering lead candidate diazoxide; shares ahead 5% premarket https://seekingalpha.com/news/3300376-soleno-nabs-u-s-patent-covering-lead-candidate-diazoxide-shares-ahead-5-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3300376-soleno-nabs-u-s-patent-covering-lead-candidate-diazoxide-shares-ahead-5-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:33 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300373\" data-ts=\"1507724880\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBRX\" target=\"_blank\">MBRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300373-moleculin-strategically-collaborates-to-develop-immune-stimulation-drug-shares-ahead-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Moleculin strategically collaborates to develop immune stimulation drug; shares ahead 6% premarket</a></h4><ul> <li>Moleculin Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a>) <a href=\"https://seekingalpha.com/pr/16965161-moleculin-announces-strategic-collaboration-develop-immune-stimulation-drug\" target=\"_blank\">announces</a> collaboration agreement with the University of Bergen to expand research on inhibition of brain metastasis by Moleculin's pre-clinical drug <a href=\"http://www.moleculin.com/technology/wp1066-2/\" target=\"_blank\">WP1066</a> and its unique ability to increase immune system response to cancer and suppression of tumor cell proliferation and survival.</li><li>Walter Klemp, Chairman and CEO of Moleculin says, \"The WP1066 project will be led by Dr.&nbsp;Frits Alan Thorsen&nbsp;and may provide critical insight on WP1066, which we anticipate will be in clinical trials soon.\"</li><li>Financial terms are not disclosed.</li><li>Shares are Moleculin Biotech are up&nbsp;<font color='green'>6%</font>&nbsp;premarket on modest volume.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3300373\" data-linked=\"Moleculin strategically collaborates to develop immune stimulation drug; shares ahead 6% premarket\" data-tweet=\"$MBRX - Moleculin strategically collaborates to develop immune stimulation drug; shares ahead 6% premarket https://seekingalpha.com/news/3300373-moleculin-strategically-collaborates-to-develop-immune-stimulation-drug-shares-ahead-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3300373-moleculin-strategically-collaborates-to-develop-immune-stimulation-drug-shares-ahead-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300372\" data-ts=\"1507724479\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TA\" target=\"_blank\">TA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300372-sell-call-on-travelcenters-of-america-from-citi\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sell call on TravelCenters of America from Citi</a></h4><ul> <li>Citi advises investors to take profits now on TravelCenters of America (NYSEMKT:<a href='https://seekingalpha.com/symbol/TA' title='TravelCenters of America LLC'>TA</a>) after watching shares run up 60% in just over a month.</li> <li>The firm cuts TravelCenters to a Sell rating and issues a price target of $4.50 with a lack of catalysts seen for future share price gains.</li> <li>TA <font color='red'>-6.54% </font>premarket to $5.00.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300372\" data-linked=\"Sell call on TravelCenters of America from Citi\" data-tweet=\"$TA - Sell call on TravelCenters of America from Citi https://seekingalpha.com/news/3300372-sell-call-on-travelcenters-of-america-from-citi?source=tweet\" data-url=\"https://seekingalpha.com/news/3300372-sell-call-on-travelcenters-of-america-from-citi\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300371\" data-ts=\"1507724420\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CASI\" target=\"_blank\">CASI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300371-casi-pharma-set-to-build-on-breakout-shares-up-28-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CASI Pharma set to build on breakout, shares up 28% premarket</a></h4><ul><li>Thinly traded micro cap CASI Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CASI' title='CASI Pharmaceuticals'>CASI</a>) is up&nbsp;<font color='green'>28%</font>&nbsp;premarket on light volume. Shares have more than doubled since its pipeline update in September.</li><li>A key looming event is <a href=\"http://www.casipharmaceuticals.com/investor-relations/news/casi-provides-pipeline-development-update\" target=\"_blank\">regulatory approval</a> of EVOMELA (melphalan) in China. The China Food and Drug Administration &#40;CFDA&#41; designated the product for Priority Review in early September, with a decision expected in four-to-six months.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294112-casi-provides-pipeline-development-update\" target=\"_blank\">CASI provides pipeline development update</a> (Sept. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3300371\" data-linked=\"CASI Pharma set to build on breakout, shares up 28% premarket\" data-tweet=\"$CASI - CASI Pharma set to build on breakout, shares up 28% premarket https://seekingalpha.com/news/3300371-casi-pharma-set-to-build-on-breakout-shares-up-28-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3300371-casi-pharma-set-to-build-on-breakout-shares-up-28-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300363\" data-ts=\"1507723551\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATHX\" target=\"_blank\">ATHX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300363-athersys-poised-for-snapback-after-yesterdays-drop-shares-up-25-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Athersys poised for snapback after yesterday&#39;s drop, shares up 25% premarket</a></h4><ul><li>Athersys (NASDAQ:<a href='https://seekingalpha.com/symbol/ATHX' title='Athersys, Inc.'>ATHX</a>) is up&nbsp;<font color='green'>25%</font>&nbsp;premarket on robust volume, encouraging action to regain (and then some) yesterday's&nbsp;<font color='red'>8%</font>&nbsp;loss.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3300164-sa-contributor-alpha-exposure-bearish-athersys-multistem-shares-9-percent\" target=\"_blank\">SA Contributor Alpha Exposure bearish on Athersys' MultiStem; shares down 9%</a> (Oct. 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3300363\" data-linked=\"Athersys poised for snapback after yesterday&#39;s drop, shares up 25% premarket\" data-tweet=\"$ATHX - Athersys poised for snapback after yesterday&#39;s drop, shares up 25% premarket https://seekingalpha.com/news/3300363-athersys-poised-for-snapback-after-yesterdays-drop-shares-up-25-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3300363-athersys-poised-for-snapback-after-yesterdays-drop-shares-up-25-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300360\" data-ts=\"1507723149\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNKD\" target=\"_blank\">MNKD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300360-mannkind-sees-q3-net-afrezza-sales-of-2m-shares-down-7-premarket-on-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MannKind sees Q3 net Afrezza sales of ~$2M; shares down 7% premarket on equity offering</a></h4><ul><li>MannKind (NASDAQ:<a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a>) slips&nbsp;<font color='red'>7%</font>&nbsp;premarket on robust volume in response to its $61M equity offering.</li><li>The company <a href=\"https://seekingalpha.com/pr/16964988-mannkind-announces-61-million-registered-direct-offering-common-stock\" target=\"_blank\">expects </a>to book between $1.8M and $2.2M of net AFREZZA sales in Q3 (gross sales: $2.6M - 3.0M). Cash and cash equivalents were ~$20.2M at the end of September.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300360\" data-linked=\"MannKind sees Q3 net Afrezza sales of ~$2M; shares down 7% premarket on equity offering\" data-tweet=\"$MNKD - MannKind sees Q3 net Afrezza sales of ~$2M; shares down 7% premarket on equity offering https://seekingalpha.com/news/3300360-mannkind-sees-q3-net-afrezza-sales-of-2m-shares-down-7-premarket-on-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3300360-mannkind-sees-q3-net-afrezza-sales-of-2m-shares-down-7-premarket-on-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300353\" data-ts=\"1507722288\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CL\" target=\"_blank\">CL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300353-suntrust-sees-upside-for-colgate-palmolive\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SunTrust sees upside for Colgate-Palmolive</a></h4><ul> <li>SunTrust lifts Colgate-Palmolive (NYSE:<a href='https://seekingalpha.com/symbol/CL' title='Colgate-Palmolive Co.'>CL</a>) to a <a href=\"https://twitter.com/ARatings/status/918078498920652805\" target=\"_blank\">Buy rating</a>.</li> <li>The investment firm hikes its price target to $85.</li> <li>Shares of Colgate are <font color='green'>up 0.48%</font> premarket to $73.25 vs. a 52-week trading range of $63.43 to $77.27.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300353\" data-linked=\"SunTrust sees upside for Colgate-Palmolive\" data-tweet=\"$CL - SunTrust sees upside for Colgate-Palmolive https://seekingalpha.com/news/3300353-suntrust-sees-upside-for-colgate-palmolive?source=tweet\" data-url=\"https://seekingalpha.com/news/3300353-suntrust-sees-upside-for-colgate-palmolive\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300325\" data-ts=\"1507721171\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNN\" target=\"_blank\">SNN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300325-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Smith &amp; Nephew (NYSE:<a href='https://seekingalpha.com/symbol/SNN' title='Smith & Nephew plc'>SNN</a>) initiated with Buy rating and $42 (11% upside) price target by Canaccord Genuity.</li><li>Universal Health Services (NYSE:<a href='https://seekingalpha.com/symbol/UHS' title='Universal Health Services Inc.'>UHS</a>) initiated with Equal Weight rating and $120 (12% upside) price target by Stephens.</li><li>Johnson &amp; Johnson (NYSE:<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a>) upgraded to Buy with $157 (17% upside) price target by Jefferies citing \"under-modeled\" pharma division.</li><li>AnaptysBio (NASDAQ:<a href='https://seekingalpha.com/symbol/ANAB' title='AnaptysBio'>ANAB</a>) price target raised to $70 (20% upside) by RBC Capital Markets.</li><li>Bluebird bio (NASDAQ:<a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a>) resumed with Hold rating and $126 (4% downside risk) price target by Jefferies.</li><li>Gilead Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a>) resumed with Overweight rating and $90 (8% upside) price target by Barclays citing upside with CAR T platform after Kite Pharma buy.</li><li>AbbVie (NYSE:<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a>) upgraded to Outperform with $105 (15% upside) by Cowen and Company.</li><li>ObsEva (NASDAQ:<a href='https://seekingalpha.com/symbol/OBSV' title='ObsEva'>OBSV</a>) price target lowered to $25 (155% upside) from $27 by H.C. Wainwright.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300325\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$SNN $SNN $UHS - Premarket analyst action - healthcare https://seekingalpha.com/news/3300325-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3300325-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300330\" data-ts=\"1507719714\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DAL\" target=\"_blank\">DAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300330-delta-air-lines-beats-0_03-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Delta Air Lines beats by $0.03, beats on revenue</a></h4><ul><li>Delta Air Lines (NYSE:<a href='https://seekingalpha.com/symbol/DAL' title='Delta Air Lines, Inc.'>DAL</a>): Q3 EPS of $1.57 <font color='green'>beats by $0.03</font>.</li><li>Revenue of $11.06B (+5.5% Y/Y) <font color='green'>beats by $20M</font>.</li><li>Shares <font color='green'>+1.33%</font> PM.</li><li><a href='https://seekingalpha.com/pr/16965123-delta-air-lines-announces-september-quarter-profit'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3300330\" data-linked=\"Delta Air Lines beats by $0.03, beats on revenue\" data-tweet=\"$DAL - Delta Air Lines beats by $0.03, beats on revenue https://seekingalpha.com/news/3300330-delta-air-lines-beats-0_03-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3300330-delta-air-lines-beats-0_03-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300326\" data-ts=\"1507719028\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNKD\" target=\"_blank\">MNKD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300326-mannkind-prices-stock-offering-6-shares-off-4-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MannKind prices stock offering at $6; shares off 4% premarket</a></h4><ul><li>MannKind (NASDAQ:<a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a>) <a href=\"https://seekingalpha.com/pr/16964988-mannkind-announces-61-million-registered-direct-offering-common-stock\" target=\"_blank\">prices </a>its direct offering of 10,166,600 shares of common stock to institutional investors at $6 per share yielding gross proceeds of ~$61M. Closing date is October 13.</li><li>Shares are down&nbsp;<font color='red'>4%</font>&nbsp;premarket on modest volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300326\" data-linked=\"MannKind prices stock offering at $6; shares off 4% premarket\" data-tweet=\"$MNKD - MannKind prices stock offering at $6; shares off 4% premarket https://seekingalpha.com/news/3300326-mannkind-prices-stock-offering-6-shares-off-4-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3300326-mannkind-prices-stock-offering-6-shares-off-4-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}